[go: up one dir, main page]

US20100189644A1 - Arginase inhibitors and methods of use - Google Patents

Arginase inhibitors and methods of use Download PDF

Info

Publication number
US20100189644A1
US20100189644A1 US12/693,863 US69386310A US2010189644A1 US 20100189644 A1 US20100189644 A1 US 20100189644A1 US 69386310 A US69386310 A US 69386310A US 2010189644 A1 US2010189644 A1 US 2010189644A1
Authority
US
United States
Prior art keywords
amino
compound
alkyl
borono
arginase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/693,863
Other languages
English (en)
Inventor
David W. Christianson
Bruce Edward Tomczuk
Richard Scott Pottorf
Andrew Vargha Colasanti
Gary Lee Olson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
University of Pennsylvania Penn
Original Assignee
University of Pennsylvania Penn
Arginetix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US12/693,863 priority Critical patent/US20100189644A1/en
Application filed by University of Pennsylvania Penn, Arginetix Inc filed Critical University of Pennsylvania Penn
Publication of US20100189644A1 publication Critical patent/US20100189644A1/en
Assigned to CORRIDOR PHARMACEUTICALS, INC. reassignment CORRIDOR PHARMACEUTICALS, INC. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: ARGINETIX, INC., IMMUNE CONTROL INC.
Assigned to THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, CORRIDOR PHARMACEUTICALS, INC. reassignment THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT reassignment NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: UNIVERSITY OF PENNSYLVANIA
Assigned to ASTRAZENECA UK LIMITED reassignment ASTRAZENECA UK LIMITED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CORRIDOR PHARMACEUTICALS, INC.
Assigned to ASTRAZENECA AB reassignment ASTRAZENECA AB ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ASTRAZENECA UK LIMITED
Priority to US14/959,765 priority patent/US10118936B2/en
Priority to US16/145,559 priority patent/US20190127395A1/en
Assigned to NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR reassignment NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR CONFIRMATORY LICENSE (SEE DOCUMENT FOR DETAILS). Assignors: THE UNIVERSITY OF PENNSYLVANIA
Priority to US16/548,681 priority patent/US20200223871A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention generally relates to enzyme inhibitors, particularly to arginase inhibitors, compositions containing these arginase inhibitors, and methods of their use for the treatment and diagnosis of conditions characterized either by abnormally high arginase activity or by abnormally low nitric oxide synthase activity.
  • the present invention is directed to inhibitors of arginase activity, which are useful for treating diseases or disorders characterized either by abnormally high arginase activity in a tissue of a mammal or by abnormally low nitric oxide synthase activity in a tissue of the mammal.
  • Embodiments of the invention provide new inhibitors of arginase, especially ⁇ , ⁇ -disubstituted ⁇ -amino carboxylic acids, particularly L-amino acids.
  • arginase especially ⁇ , ⁇ -disubstituted ⁇ -amino carboxylic acids, particularly L-amino acids.
  • R 1 the other ⁇ -position sidechain, which is referred to herein as R 1 , beneficially affects the pharmacological characteristics of the compound.
  • the invention is directed to compounds of formula IA or formula IB:
  • said dashed line represents an optional double bond
  • X 1 is —(CH 2 )— or, when said double bond is present between X 1 and X 2 , X 1 is —(CH)—;
  • X 3 is —(CH 2 )— or —(NR 2 )—, or, when said double bond is present between X 1 and X 2 or between X 2 and X 3 , X 2 is —(CH)— or N;
  • X 3 is —(CH 2 )—, a heteroatom moiety selected from the group consisting of —S—, —O— and —(NR 2 )— or, when said double bond is present between X 2 and X 3 or between X 3 and X 4 , X 3 is —(CH) ⁇ or N;
  • X 4 is —(CH 2 )— or, when said double bond is present between X 3 and X 4 , X 4 is —(CH)— and is in the trans configuration;
  • X 3 is —(NR 2 )— when Z is
  • R 1 is a monovalent moiety other than H; or R 1 and said ⁇ -carboxylate, when taken together, form a lactone; and
  • R 2 is, independently, H, methyl, or ethyl.
  • the compounds of formula IA and IB are the L-stereoisomer forms (as illustrated below) of the compounds, defined herein as compounds of formula Ia and Ib, respectively:
  • R 1 is (C 1 -C 20 )alkyl, hydroxy(C 1 -C 20 )alkyl, hydroxy(C 2 -C 20 )alkenyl, (C 2 -C 20 )alkenyl, (C 2 -C 20 )alkynyl, (C 5 -C 50 )aryl, (C 3 -C 50 )heteroaryl having at least one heteroatom selected from N, O, and S; (C 5 -C 50 )aryl(C 1 -C 20 )alkyl, (C 3 -C 50 )heteroaryl(C 1 -C 20 )alkyl, (C 2 -C 50 )heterocycloalkyl(C 1 -C 50 )alkyl, (C 5 -C 50 )aryloxy(C 1 -C 20 )alkyl, (C 5 -C 50 )arylthio(C 1 -C 50 )alkyl, (C 3 -
  • each R x is independently (C 1 -C 20 )alkylenyl
  • R y is (C 1 -C 6 )alkyl, (C 5 -C 50 )aryl(C 1 -C 6 )alkyl, (C 5 -C 50 )aryloxy(C 1 -C 6 )alkyl, hydroxyl, (C 1 -C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, N(R 3 ) 2 , (C 5 -C 50 )aryl, (C 3 -C 50 )heteroaryl having at least one heteroatom selected from N, O, and S; heterocyclyl, (C 5 -C 50 )aryl(C 1 -C 6 )alkyl, or (C 3 -C 50 )heteroaryl(C 1 -C 6 )alkyl;
  • R z is (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, —R x —O—(C 1 -C 6 )alkyl, (C 5 -C 50 )aryl, (C 3 -C 50 )heteroaryl having at least one heteroatom selected from N, O, and S; (C 5 -C 50 )aryl(C 1 -C 6 )alkyl, or (C 3 -C 50 )heteroaryl(C 1 -C 6 )alkyl;
  • R 3 is, independently, H, (C 1 -C 6 )alkyl, or (C 1 -C 6 )alkyl-N(R 4 ) 2 ;
  • R 4 is, independently, H or (C 1 -C 6 )alkyl
  • R 5 is —C( ⁇ O)—(C 1 -C 6 )alkyl, —C( ⁇ O)—(C 5 -C 50 )aryl, —SO 2 —(C 5 -C 50 )aryl, —C( ⁇ O)NR 3 R 4 , —C( ⁇ O)—NR 4 (C 5 -C 50 )aryl, or —C( ⁇ O)-heterocycle;
  • R 3 and R 5 together form a (C 2 -C 10 )heterocycloalkyl
  • L is an aliphatic or aromatic linkage
  • Y is a residue of an imageable moiety, peptide, peptidomimetic, or carbohydrate.
  • compositions comprising:
  • the invention is directed to methods of inhibiting arginase in a mammal, comprising the step of:
  • the invention is directed to methods of treating an arginase-related disorder in a mammal, comprising the step of:
  • the invention is directed to methods of diagnosing arginase over-expression in a patient, comprising the step of:
  • R 1 is a labeled derivative thereof
  • the invention is directed to methods of diagnosing arginase over-expression in a patient, comprising the step of:
  • the invention is directed to methods for radioimaging a patient, comprising the steps of:
  • Y is an imageable moiety
  • the invention is directed to methods of inhibiting arginase, comprising the step of:
  • the arginase is a yeast, bacterial, parasitic, or mammalian arginase.
  • the mammalian arginase is human type I arginase or human type II arginase (e.g., human penile arginase).
  • the invention is directed to diagnostic compositions, comprising:
  • R 1 is a labeled derivative thereof.
  • the invention is directed to diagnostic compositions, comprising:
  • the invention is directed to methods of treating a disease or condition associated with up-regulation of arginase in a mammal, comprising the step of:
  • said disease or condition is a gastrointestinal disease, a pulmonary inflammatory disease, a sexual arousal disorder, a cardiovascular disorder, a hemolytic disorder, an autoimmune disease, wound healing, a disease caused by parasitic protozoa, a disease caused by bacteria, a cancer, pre-term labor, psoriasis, or a combination thereof.
  • the invention is directed to methods of providing relief from immune suppression in a mammal, comprising the step of:
  • said mammal is suffering from a disease or condition selected from the group consisting of a chronic infectious disease, a bacterial infection, a parasitic infection, trauma, leprosy, tuberculosis, liver transplantation, a cancer, and combinations thereof.
  • a disease or condition selected from the group consisting of a chronic infectious disease, a bacterial infection, a parasitic infection, trauma, leprosy, tuberculosis, liver transplantation, a cancer, and combinations thereof.
  • the invention is directed to methods of inhibiting the production of ornithine in a mammal suffering from at least one tumor, comprising the step of:
  • compositions comprising:
  • PDE1 phosphodiesterase-1
  • PDE2 phosphodiesterase-2
  • PDE5 phosphodiesterase-5
  • the invention is directed to processes for preparing a substituted boronic acid of formula I:
  • R is methyl, ethyl, or t-butyl
  • X 1 is —(CH 2 )—
  • X 2 is —(CH 2 )—
  • X 3 is —(CH 2 )—
  • X 4 is —(CH 2 )—
  • R 1 is a monovalent moiety other than H; or R 1 and said ⁇ -carboxylate, when taken together, form a lactone.
  • FIGS. 1 and 2 illustrate some exemplary arginase inhibitors in prodrug form according to certain exemplary embodiments hereof.
  • FIGS. 3 through 17 schematically illustrate the synthesis of several exemplary compounds of the invention.
  • FIG. 18 illustrates some known arginase inhibitors and several improved analogs thereof in accordance with certain embodiments of the invention.
  • FIGS. 19 through 24 illustrate some exemplary R 1 sidechains according to certain embodiments of the present invention.
  • Embodiments of the present invention relates to enzyme inhibitors, particularly to arginase inhibitors, compositions thereof, and methods of their use for the treatment and diagnosis of conditions characterized either by abnormally high arginase activity or by abnormally low nitric oxide synthase activity.
  • administering refers to the act of giving or providing a composition or compound to a patient by the patient themselves or by a caregiver, such as a medical professional or the like, including the act of ingestion by or application to the patient or the like wherein the composition or compound can exert its effects.
  • an effective amount refers to an amount of the active ingredient as described herein that may be effective to prevent, reduce or eliminate the symptoms or condition.
  • treating and “treatment” refer to the preventative, curative, and palliative treatment of a condition malady or affliction, especially in a human patient in need of such treatment.
  • “pharmaceutically-acceptable” refers to those compounds, materials, compositions, or dosage forms that are, within the scope of sound medical judgment, suitable for contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem complications commensurate with a reasonable benefit/risk ratio.
  • pharmaceutically-acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof, including acid addition salts and base addition salts.
  • examples of pharmaceutically-acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the term “acid addition salt” refers to the corresponding salt derivative of a parent compound that has been prepared by the addition of an acid.
  • the pharmaceutically-acceptable salts include the conventional salts or the quaternary ammonium salts of the parent compound formed, for example, from inorganic or organic acids.
  • such conventional salts include, but are not limited to, those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, adipic, alginic, aspartic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, benzenesulfonic, toluenesulfonic, methanesulfonic, 2-napthalenesulfonic, ethane disulfonic, oxalic, isethionic, glucoheptanoic, glycerophosphoric, hemisulfanic, heptanoic,
  • base addition salt refers to the corresponding salt derivative of a parent compound that has been prepared by the addition of a base.
  • the basic nitrogen-containing groups can be quaternized with such agents as lower alkyl halides, such as methyl, ethyl, propyl, and butyl chloride, bromides, and iodides; dialkyl sulfates like dimethyl, diethyl, dibutyl, and diamyl sulfates, long chain halides such as decyl, lauryl, myristyl and stearyl chlorides, bromides and iodides, aralkyl halides like benzyl and phenethyl bromides, and others.
  • the pharmaceutically-acceptable salts include the conventional salts or the quaternary ammonium salts of the parent compound formed, for example, from inorganic or organic bases.
  • such conventional salts include, but are not limited to, those derived from inorganic bases such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide and ammonium hydroxide and the salts prepared from organic amines, such as methyl amine, ethyl amine, isopropyl amine, piperidine, piperizine, pyrrolidine, ethanolamine, morpholine, diazapine, ethylene diamine, pyridine, quinoline, quinuclidine, and the like.
  • “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration.
  • the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active compound, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
  • dosage unit refers to physically discrete units suited as unitary dosages for the particular patient to be treated. Each unit may contain a predetermined quantity of active compound(s) calculated to produce the desired therapeutic effect(s) in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the invention may be dictated by (a) the unique characteristics of the active compound(s) and the particular therapeutic effect(s) to be achieved, and (b) the limitations inherent in the art of compounding such active compound(s).
  • patient refers to an animal, including a mammal, preferably a human.
  • R a is, independently, H, OH, alkyl (optionally substituted with one or more R 4 ), alkoxy (optionally substituted with one or more R 4 ), halo, trifluoromethyl, alkanoyloxy (optionally substituted with one or more R 4 ), methylenedioxy, benzyloxy (optionally substituted with one or more R 4 ), phenyloxy (optionally substituted with one or more R 4 ), naphthyloxy (optionally substituted with one or more R 4 ), nitro, trifluoromethoxy, nitrile, alkenyl (optionally substituted with one or more R 4 ), alkynyl, sulfoxide, sulfonyl, sulfonamido, aryl (optionally substituted with one or more R 4 ), heteroaryl (optionally substituted with one or more R 4 ), aryloyl (optionally substituted with one or more R 4 ), heteroaryl (optionally substituted
  • R 4 is (C 1 -C 20 )alkyl, (C 2 -C 20 )alkenyl, (C 2 -C 20 )alkynyl, halo, nitrile, nitro, (C 5 -C 50 )aryl, (C 3 -C 50 )heteroaryl having at least one heteroatom selected from N, O, and S; (C 5 -C 50 )aryl(C 1 -C 20 )alkyl, heteroaryl(C 1 -C 20 )alkyl, (C 5 -C 50 )aryloxy(C 1 -C 20 )alkyl, heteroaryloxy(C 1 -C 20 )alkyl, (C 5 -C 50 )arylamino(C 1 -C 20 )alkyl, heteroarylamino(C 1 -C 20 )alkyl, amino(C 1 -C 20 )alkyl, —R x —C( ⁇ O)—R y
  • Alkyl refers to an aliphatic hydrocarbon chain of 1 to about 20 carbon atoms, preferably 1 to 10 carbon atoms, more preferably, 1 to 6 carbon atoms, and even more preferably, 1 to 4 carbon atoms and includes straight and branched chains such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tent-butyl, n-pentyl, isopentyl, neo-pentyl, n-hexyl, and isohexyl.
  • Lower alkyl refers to alkyl having 1 to 4 carbon atoms.
  • Alkyl groups can be optionally substituted with one or more R a , as defined herein.
  • Alkylenyl refers to a divalent counterpart of “alkyl,” as defined herein (e.g., methyleneyl, ethyleneyl, propyleneyl, etc.). Alkylenyl groups can be optionally substituted with one or more R a , as defined herein.
  • Alkenyl or “olefinic,” as used herein, refers to an alkyl group of at least two carbon atoms having one or more double bonds, wherein alkyl is as defined herein. Alkenyl groups can be optionally substituted with one or more R a , as defined herein.
  • Haldroxy(C 1 -C 20 )alkyl refers to an alkyl group, as defined herein, substituted with at least one hydroxy group.
  • Haldroxy(C 2 -C 20 )alkenyl refers to an alkenyl group, as defined herein, substituted with at least one hydroxy group.
  • Alkynyl refers to an alkyl group of at least two carbon atoms having one or more triple bonds, wherein alkyl is as defined herein. Alkynyl groups can be optionally substituted with one or more R a , as defined herein.
  • Aryl refers to an optionally substituted, mono-, di-, tri-, or other multicyclic aromatic ring system having from about 5 to about 50 carbon atoms (and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein), with from about 6 to about 10 carbons being preferred.
  • Non-limiting examples include, for example, phenyl, naphthyl, anthracenyl, and phenanthrenyl.
  • Aryl groups can be optionally substituted with one or more R a , as defined herein.
  • Heteroaryl refers to an optionally substituted, mono-, di-, tri-, or other multicyclic aromatic ring system that includes at least one, and preferably from 1 to about 4 sulfur, oxygen, or nitrogen heteroatom ring members. Heteroaryl groups can have, for example, from about 3 to about 50 carbon atoms (and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein), with from about 4 to about 10 carbons being preferred.
  • heteroaryl groups include, for example, pyrryl, furyl, pyridyl, 1,2,4-thiadiazolyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, thiophenyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, purinyl, carbazolyl, benzimidazolyl, and isoxazolyl.
  • Heteroaryl groups can be optionally substituted with one or with one or more R a , as defined herein.
  • (C 5 -C 50 )Aryl(C 1 -C 20 )alkyl refers to the group R—R′— where R is an aryl group and R′ is an alkylenyl, as defined herein.
  • Heteroaryl(C 1 -C 20 )alkyl refers to the group R—R′— where R is a heteroaryl group and R′ is an alkylenyl, as defined herein.
  • (C 5 -C 50 )aryloxy(C 1 -C 20 )alkyl refers to the group R—O—R′— where R is an aryl group and R′ is an alkylenyl, as defined herein.
  • Heteroaryloxy(C 1 -C 20 )alkyl refers to the group R—O—R′— where R is a heteroaryl group and R′ is an alkylenyl, as defined herein.
  • (C 5 -C 50 )arylamino(C 1 -C 20 )alkyl refers to the group R—NH—R′— where R is an aryl group and R′ is an alkylenyl, as defined herein.
  • Heteroaryloxyamino(C 1 -C 20 )alkyl refers to the group R—NH—R′— where R is a heteroaryl group and R′ is an alkylenyl, as defined herein.
  • Amino(C 1 -C 20 )alkyl refers to the group N(R′′)—R′— where R′′ is a hydrogen or (C 1 -C 6 )alkyl group and R′ is an alkylenyl, as defined herein.
  • Cycloalkyl refers to an optionally substituted, alkyl group having one or more rings in their structures having from 3 to about 20 carbon atoms (and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein), with from 3 to about 10 carbon atoms being preferred. Multi-ring structures may be bridged or fused ring structures.
  • Groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclooctyl, 2-[4-isopropyl-1-methyl-7-oxa-bicyclo[2.2.1]heptanyl], 2-[1,2,3,4-tetrahydro-naphthalenyl], and adamantyl.
  • Heterocycloalkyl refers to an optionally substituted, cycloalkyl group having one or more rings in their structures having from 2 to about 20 carbon atoms (and all combinations and subcombinations of ranges and specific numbers of carbon atoms therein), with from 2 to about 10 carbon atoms being preferred, in addition to at least one heteroatom independently selected from the group consisting of N, O and S. Multi-ring structures may be bridged or fused ring structures.
  • Groups include, but are not limited, to aziridinyl, pyrrolidinyl, pyrrolidino, piperidinyl, piperidino, piperazinyl, piperazino, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, tetrahydrofuranyl, tetrahydrothiofuranyl, tetrahydropyranyl, and pyranyl.
  • Halo or “halogen,” as used herein, refers to chloro, bromo, fluoro, and iodo.
  • Alkoxy refers to the group R—O— where R is an alkyl group of 1 to 6 carbon atoms.
  • Alkoxycarbonyl refers to the group R—O—C( ⁇ O)— where R is an alkyl group of 1 to 6 carbon atoms.
  • Alkanoyl refers to the group R—C( ⁇ O)— where R is an alkyl group of 1 to 6 carbon atoms.
  • Alkanoyloxy refers to the group R—C( ⁇ O)—O— where R is an alkyl group of 1 to 6 carbon atoms.
  • Alkylaminocarbonyl refers to the group R—NH—C( ⁇ O)— where R is an alkyl group of 1 to 6 carbon atoms.
  • Alkylcarbonylamino refers to the group R—C( ⁇ O)—NH where R is an alkyl group of 1 to 6 carbon atoms.
  • Heteroarylmethyl refers to the group R—CH 2 — where R is a heteroaryl group, as defined herein.
  • Heteroarylmethyloxy refers to the group R—CH 2 —O— where R is a heteroaryl group, as defined herein.
  • Heteroaryloxy refers to the group R—O— where R is a heteroaryl group, as defined herein.
  • Heteroarylmethyloxy refers to the group R—CH 2 —O— where R is a heteroaryl group, as defined herein.
  • Heterocycle refers to a stable 5- to 7-membered monocyclic or bicyclic or 7- to 10-membered bicyclic heterocyclic ring, or radical thereof, that is saturated, partially unsaturated or unsaturated (aromatic), and which contains carbon atoms and from 1 to 4 heteroatoms independently selected from the group consisting of N, O and S and including any bicyclic group in which any of the above defined heterocyclic rings is fused to a benzene ring.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized.
  • the heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure.
  • heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. If specifically noted, a nitrogen atom in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds one, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than one.
  • heterocycles include, but are not limited to, 1H-indazole, 2-pyrrolidonyl, 2H,6H-1,5,2 dithiazinyl, 2H-pyrrolyl, 3H-indolyl, 4-piperidonyl, 4aH-carbazole, 4H-quinolizinyl, 6H-1,2,5-thiadiazinyl, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazalonyl, carbazolyl, 4H-carbazolyl, ⁇ -, ⁇ -, or ⁇ -carbolinyl, chromanyl, chromenyl, cinnolinyl, deca
  • Preferred heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, indolyl, benzimidazolyl, 1H-indazolyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, or isatinyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.
  • “Sulfoxide,” as used herein, refers to a compound or moiety containing the group —S( ⁇ O)—.
  • “Sulfonamido,” as used herein, refers to a moiety containing the group —S(O) 2 —NH—.
  • “Sulfonyl,” as used herein, refers to a moiety containing the group —S(O) 2 —.
  • Aliphatic linkage refers to any divalent alkylenyl group (e.g., methyleneyl, ethyleneyl, propyleneyl, etc.), including groups having the general formula —(CH 2 ) m —, wherein m is an integer from 1 to 6.
  • “Aromatic linkage,” as used herein, refers to any divalent aryl group, such as a —(C 4 H 4 )— group.
  • Residue of an imageable moiety refers to any moiety, as generally known in the art and as specifically defined herein, that comprises one or more groups capable of detection either directly or indirectly in an in vivo or in vitro diagnostic imaging procedure, and comprises, e.g., one or more moieties that emit or may be caused to emit detectable radiation (e.g., by radioactive decay, fluorescence excitation, spin resonance excitation, etc.), groups that affect local electromagnetic fields (e.g., paramagnetic, superparamagnetic, ferromagnetic, or ferromagnetic species), groups that absorb or scatter radiation energy (e.g., chromophores, particles (including gas or liquid containing vesicles), heavy elements and compounds thereof, etc.), and groups that generate a detectable substance (e.g., gas microbubble generators).
  • detectable radiation e.g., by radioactive decay, fluorescence excitation, spin resonance excitation, etc.
  • groups that affect local electromagnetic fields e.g., par
  • imageable moieties may be selected from the group consisting of a gamma ray emitting radioisotopes, positron emitting radioisotopes, a magnetic resonance imaging contrast agents (e.g., gadolinium chelates), X-ray contrast agents (e.g., iodinated radioopaque aromatic compounds), or an ultrasound contrast agent (e.g., liposomes comprising an echogenic compound).
  • a gamma ray emitting radioisotopes positron emitting radioisotopes
  • a magnetic resonance imaging contrast agents e.g., gadolinium chelates
  • X-ray contrast agents e.g., iodinated radioopaque aromatic compounds
  • an ultrasound contrast agent e.g., liposomes comprising an echogenic compound
  • “Peptide,” as used herein, means a linear compound that consists of two or more amino acids (as defined herein) that are linked by means of a peptide bond.
  • a “peptide” as used in the presently claimed invention is intended to refer to a moiety with a molecular weight of less than about 10,000 Daltons, preferable less than about 5,000 Daltons, and more preferably less than about 2,500 Daltons.
  • the term “peptide” also includes compounds containing both peptide and non-peptide components, such as pseudopeptide or peptidomimetic residues or other non-amino acid components.
  • a “residue of peptide” means that a molecule where a portion of a peptide has been removed to accommodate a bond to another molecule, such as in the R 1 group of the compounds of the invention.
  • “Pseudopeptide” or “peptidomimetic,” as used herein, means a compound that mimics the structure of an amino acid residue or a peptide, for example, by using linking groups other than amide linkages between the peptide mimetic and an amino acid residue (pseudopeptide bonds) or by using non-amino acid substituents or a modified amino acid residue.
  • a “residue of peptidomimetic” means that a molecule where a portion of a pseudopeptide or peptidomimetic has been removed to accommodate a bond to another molecule, such as in the R 1 group of the compounds of the invention.
  • Carbohydrate as used herein, means an organic compound having aldehydes or ketones with many hydroxyl groups added, usually one on each carbon atom that is not part of the aldehyde or ketone functional group, including sugars, starches, celluloses, and gums.
  • a “residue of carbohydrate” means that a molecule where a portion of a carbohydrate has been removed to accommodate a bond to another molecule, such as in the R 1 group of the compounds of the invention.
  • arginase The activity of the liver enzyme, arginase, permits disposal of nitrogenous wastes that result from protein catabolism.
  • arginase regulates cellular concentrations of arginine and ornithine, which are used for biosynthetic reactions.
  • Arginine is used, by way of example, in the synthesis of nitric oxide.
  • arginase activity is reciprocally coordinated with the activity of the enzyme, nitric oxide synthase. Reciprocal coordination of the activities of arginase and nitric oxide synthase (NOS) modulates NO-dependent cytotoxicity.
  • Arginase catalyzes divalent cation-dependent hydrolysis of L-arginine to form L-ornithine and urea.
  • the enzyme is currently known to serve three important functions: (1) production of urea, (2) production of ornithine, and (3) regulation of substrate arginine levels for nitric oxide synthase.
  • Urea production provides a mechanism to excrete nitrogen in the form of a highly soluble, non-toxic compound, thus avoiding the potentially dangerous consequences of high ammonia levels.
  • L-Ornithine is a precursor for the biosynthesis of polyamines, spermine, and spermidine, which have important roles in cell proliferation and differentiation.
  • arginase modulates production of nitric oxide by regulating the levels of arginine present within tissues.
  • Non-reactive arginine analogs for use as enzyme inhibitors or receptor antagonists is a rapidly growing area of medicinal chemical research. Since both NO synthase and arginase compete for the same substrate, the possibility of reciprocal regulation of both arginine metabolic pathways has been explored. Furthermore, N ⁇ -hydroxy-L-arginine (L-HO-Arg), an intermediate in the NO synthase reaction, is an endogenous arginase inhibitor. The phenomenon of reciprocal regulation between arginase and NO synthase has only recently been examined. In the internal anal sphincter (IAS), it was shown that exogenous administration of arginase attenuates NO synthase-mediated non-adrenergic and non-cholinergic (NANC) nerve-mediated relaxation.
  • IAS internal anal sphincter
  • an excess of arginase has also recently been associated with a number of pathological conditions that include gastric cancer, certain forms of liver injury, and pulmonary hypertension following orthotopic liver transplantation.
  • high levels of arginase can cause impairment in NANC-mediated relaxation of the IAS.
  • arginase pre-treatment causes significant suppression of the NANC nerve-mediated relaxation of the IAS that is mediated primarily via the L-arginine-NO synthase pathway. Impairment in NANC relaxation by excess arginase may be related to L-arginine depletion. Furthermore, suppressed relaxation could be restored by the arginase inhibitor L-HO-Arg.
  • arginase inhibitors such as L-OH-Arg can not be selective since it also serves as a NO synthase substrate. Because of this, the exact role of arginase in pathophysiology and the potential therapeutic actions of arginase inhibitors remains undetermined.
  • Rat liver arginase is a trimeric metalloenzyme which contains a bi-nuclear manganese cluster in the active site of each subunit. This bi-nuclear cluster is required for maximal catalytic activity.
  • X-ray crystal structures of human arginase I and human arginase II are also available. See, e.g., Di Costanzo et al., Proc. Natl. Acad. Sci. (USA) 102, 13058 (2005) (X-ray crystal structures of human arginase I); and Cama et al., Biochemistry 42, 8445 (2003) (X-ray crystal structures of human arginase II).
  • the C ⁇ -R 1 groups of the invention replace the C ⁇ -H groups of the parent compounds, namely ABH, BEC, and nor-NOHA, which are illustrated in FIG. 18 .
  • the addition of the R 1 groups can be selected to target binding interactions in the outer active site cleft and the region flanking the outer active site clefts of parasitic arginase, bacterial arginase, and arginases I and II. Without intending to be bound by theory, the inventors suggest that these R 1 -substituted compounds have increased interactions with the target protein(s) that result in increased potencies or selectivities (or both) over compounds in the prior art.
  • Embodiments of the present invention therefore is directed, in part, to compounds of formula IA or formula IB:
  • stereoisomers especially the L stereoisomers of the amino acid), lactone prodrugs, or pharmaceutically-acceptable salts thereof;
  • said dashed line represents an optional double bond
  • X 1 is —(CH 2 )— or, when said double bond is present between X 1 and X 2 , X 1 is (CH)—;
  • X 2 is —(CH 2 )— or (NR 2 )—, or, when said double bond is present between X 1 and X 2 or between X 2 and X 3 , X 2 is —(CH)— or N;
  • X 3 is —(CH 2 )—, a heteroatom moiety selected from the group consisting of —S—, —O— and —(NR 2 )— or, when said double bond is present between X 2 and X 3 or between X 3 and X 4 , X 3 is —(CH)— or N;
  • X 4 is —(CH 2 )— or, when said double bond is present between X 3 and X 4 , X 4 is —(CH)— and is in the trans configuration;
  • X 3 is —(NR 2 )— when Z is
  • R 1 is a monovalent moiety other than H; or R 1 and said ⁇ -carboxylate, when taken together, form a lactone; and
  • R 2 is, independently, H, methyl, or ethyl.
  • the compounds of formula IA and IB are referred to herein as the “ L -stereoisomer” forms (as illustrated below) of the compounds, defined herein as compounds of formula Ia and Ib, respectively.
  • Compounds corresponding to the so-called “ D -stereoisomers” would have the opposite stereochemical coniduration at the ⁇ -carbon in these figures:
  • the S-stereochemistry generally occurs only in a limited case, typically when R 1 is a lower priority group, such as methyl, ethyl, propyl, and n-butyl.
  • R 1 is a lower priority group
  • the stereochemistry is R.
  • the preferred stereochemistry is the form that more effectively permits the molecule to function as an arginase inhibitor. Indeed, structural and functional studies have established that the ⁇ C stereochemistry as defined immediately above is preferred for tight binding in the enzyme active site; whereas stereoisomers with the opposite configuration do not bind as tightly or are less efficacious.
  • the stereoisomers may be defined where the ProS hydrogen of glycine depicted below is replaced by an R 1 side chain that fits into the enzyme active site.
  • R 1 replaces the ProR hydrogen of glycine.
  • the designation R or S for the stereoisomers depends upon the hierarchy based on the atoms connected to the chiral carbon. For instance, if R 1 is methyl and X 1 . . . is —(CH 2 ) 4 B(OH) 2 then the chirality will be S. However, if R 1 is methyl and X 1 . . .
  • R 1 is (CH 2 )OH and X 1 . . . is —(CH 2 ) 4 B(OH) 2 then the chirality will be R.
  • R 1 groups at the ⁇ -position of an amino acid is a difficult synthetic process as judged by the lack of commercially available ⁇ , ⁇ -disubstituted amino acids. See, e.g., Vogt et al., Org. Biomol. Chem. 5, 406-30 (2007).
  • one or both of the R 1 and boronoalkyl side chains needs to be introduced via alkylation reactions onto a suitably protected amino acid scaffold.
  • the chemistry described herein discloses a novel process of hydroboration of a crotyl group to produce the requisite terminal boronic acids in an amino acid scaffold. See, Yamamoto et al., Tetrahedron 60, 10695-700 (2004).
  • R 1 group to the known boronic acid- and N-hydroxy guanidine-type inhibitors can be selected to target binding interactions in the outer active site cleft and the region flanking the outer active site clefts of parasitic arginase, bacterial arginase, and arginases I and II.
  • R 1 substituted compounds would have increased interactions with the target protein which would result in increased potencies or selectivities over the prior art.
  • syntheses of these R 1 groups at the ⁇ -position of an amino acid is a difficult synthetic process as judged by the lack of commercially available ⁇ , ⁇ -disubstituted amino acids. See, Vogt et al., Org. Biomol. Chem. 5, 406-30 (2007).
  • R 1 and boronoalkyl side chains needs to be introduced via alkylation reactions onto a suitably protected amino acid scaffold.
  • the chemistry described herein discloses a novel process of hydroboration of a crotyl group to produce the requisite terminal boronic acids in an amino acid scaffold. See, Yamamoto et al., Tetrahedron 60, 10695-700 (2004).
  • R 1 is (C 1 -C 20 )alkyl, hydroxy(C 1 -C 20 )alkyl, hydroxy(C 2 -C 20 )alkenyl, (C 2 -C 20 )alkenyl, (C 2 -C 20 )alkynyl, (C 5 -C 50 )aryl, (C 3 -C 50 )heteroaryl having at least one heteroatom selected from N, O, and S; (C 5 -C 50 )aryl(C 1 -C 20 )alkyl, (C 3 -C 50 )heteroaryl(C 1 -C 20 )alkyl, (C 2 -C 50 )heterocycloalkyl(C 1 -C 20 )alkyl, (C 5 -C 50 )aryloxy(C 1 -C 20 )alkyl, (C 5 -C 50 )arylthio(C 1 -C 20 )alkyl, (C 3 -
  • each R x is independently (C 1 -C 20 )alkylenyl
  • R y is (C 1 -C 6 )alkyl, (C 5 -C 50 )aryl(C 1 -C 6 )alkyl, (C 5 -C 50 )aryloxy(C 1 -C 6 )alkyl, hydroxyl, (C 1 -C 6 )alkoxy, (C 3 -C 8 )cycloalkyl, N(R 3 ) 2 , (C 5 -C 50 )aryl, (C 3 -C 50 )heteroaryl having at least one heteroatom selected from N, O, and S; heterocyclyl, (C 5 -C 50 )aryl(C 1 -C 6 )alkyl, or (C 3 -C 50 )heteroaryl(C 1 -C 6 )alkyl;
  • R z is (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, —R x —O—(C 1 -C 6 )alkyl, (C 5 -C 50 )aryl, (C 3 -C 50 )heteroaryl having at least one heteroatom selected from N, O, and S; (C 5 -C 50 )aryl(C 1 -C 6 )alkyl, or (C 3 -C 50 )heteroaryl(C 1 -C 6 )alkyl;
  • R 3 is, independently, H, (C 1 -C 6 )alkyl, or (C 1 -C 6 )alkyl-N(R 4 ) 2 ;
  • R 4 is, independently, H or (C 1 -C 6 )alkyl
  • R 5 is —C( ⁇ O)—(C 1 -C 6 )alkyl, —C( ⁇ O)—(C 5 -C 50 )aryl, —SO 2 —(C 5 -C 50 )aryl, —C( ⁇ O)NR 3 R 4 , —C( ⁇ O)—NR 4 (C 5 -C 50 )aryl, or —C( ⁇ O)-heterocycle;
  • R 3 and R 5 together form a (C 2 -C 10 )heterocycloalkyl
  • L is an aliphatic or aromatic linkage
  • Y is a residue of an imageable moiety, peptide, peptidomimetic, or carbohydrate.
  • R 1 is (C 1 -C 20 )alkyl, hydroxy(C 1 -C 20 )alkyl, hydroxy(C 2 -C 20 )alkenyl, (C 2 -C 20 )alkenyl, (C 2 -C 20 )alkynyl, halo, (C 5 -C 50 )aryl, (C 3 -C 50 )heteroaryl having at least one heteroatom selected from N, O, and S; (C 5 -C 50 )aryl(C 1 -C 20 )alkyl, (C 3 -C 50 )heteroaryl(C 1 -C 20 )alkyl, (C 5 -C 50 )aryloxy(C 1 -C 20 )alkyl, (C 3 -C 50 )heteroaryloxy(C 1 -C 20 )alkyl, (C 5 -C 50 )arylamino(C 1 -C 20 )alkyl, heteroaryla
  • R 1 and said ⁇ -carboxylate when taken together, form a lactone having 4 to 7 ring atoms;
  • each R x is independently (C 1 -C 6 )alkylenyl
  • R y is (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, N(R 3 ) 2 , (C 5 -C 50 )aryl, (C 3 -C 50 )heteroaryl having at least one heteroatom selected from N, O, and S; (C 5 -C 50 )aryl(C 1 -C 6 )alkyl, or (C 3 -C 50 )heteroaryl(C 1 -C 6 )alkyl;
  • R z is (C 1 -C 6 )alkyl, (C 3 -C 8 )cycloalkyl, (C 5 -C 50 )aryl, (C 3 -C 50 )heteroaryl having at least one heteroatom selected from N, O, and S; (C 5 -C 50 )aryl(C 1 -C 6 )alkyl, or (C 3 -C 50 )heteroaryl(C 1 -C 6 )alkyl;
  • R 3 is, independently, H or (C 1 -C 6 )alkyl
  • L is an aliphatic or aromatic linkage
  • Y is a residue of an imageable moiety, peptide, peptidomimetic, or carbohydrate.
  • R 1 is (C 1 -C 20 )alkyl, hydroxy(C 1 -C 20 )alkyl, (C 2 -C 20 )alkenyl, (C 5 -C 50 )aryl, (C 5 -C 50 )aryl(C 1 -C 20 )alkyl, (C 3 -C 50 )heteroaryl(C 1 -C 20 )alkyl, (C 5 -C 50 )aryloxy(C 1 -C 20 )alkyl, amino(C 1 -C 20 )alkyl, —R x —C( ⁇ O)—R y , —R x —C( ⁇ O)—O—R y , —R x —O—R z , —R x —O—R x —NR 3 R 5 , —R x —NR 3 R 5 , —R x —O—C( ⁇ O)—R y , (C
  • R 1 groups may be unsubstituted or substituted by one or more R a groups as defined hereinabove (e.g., one or more hydrogen atoms have been replaced with an R a group).
  • R x is (C 1 -C 6 )alkylenyl.
  • R y is hydroxyl, (C 1 -C 6 )alkoxy, N(R 3 ) 2 , or heterocyclyl.
  • R z is —R x —O—(C 1 -C 6 )alkyl.
  • R 4 is, independently, H or (C 1 -C 4 )alkyl
  • R 5 is —C( ⁇ O)—(C 1 -C 6 )alkyl, —C( ⁇ O)—(C 5 -C 10 )aryl, —SO 2 —(C 5 -C 10 )aryl, —C( ⁇ O)NR 3 R 4 , —C( ⁇ O)—NR 4 (C 5 -C 10 )aryl, or —C( ⁇ O)-heterocycle.
  • R 1 preferably comprising an —(CH 2 ) x — group, where x is an integer from 1 to 3, preferably 1, adjacent to the ⁇ -carbon atom, so that there is no substantial steric bulk immediately adjacent to the stereocenter of the amino acid.
  • R 1 is a hydroxy(C 1 -C 20 )alkyl, preferably hydroxy(C 1 -C 6 )alkyl, more preferably hydroxy(C 1 -C 4 )alkyl.
  • R 1 is a hydroxy(C 2 -C 20 )alkenyl, preferably hydroxy(C 2 -C 6 )alkenyl, more preferably hydroxy(C 2 -C 4 )alkenyl.
  • the compounds of the invention are selected from the group consisting of:
  • pharmaceutically acceptable salts thereof examples include addition salts of hydrochloric and frifluoroacetic acid.
  • the L-stereoisomers of the foregoing compounds are preferred embodiments of this invention. More particularly, the preferred embodiments of this invention include those compounds analogous (S)-ABH or (S)-nor NOHA (see FIG. 18 ), in which the (R)-proton has been stereospecificly replaced with an R 1 group as described herein. These specific derivatives possess the most potency for the inhibition or arginase (lower K i values, see Example 69, below).
  • Each of the single enantiomeric compounds 47a and 47b were converted to final single enantiomeric compounds 1ar and 1as, respectively by unambiguous chemistry.
  • Final compounds 1ar and 1as were tested for arginase inhibition.
  • the enantiomer with the proposed R-configuration, compound 1ar possessed the most potency as an arginase inhibitor by two orders of magnitude compared to compound 1as.
  • X 2 is —S— or —O—.
  • X 2 is —S—.
  • X 2 is —O—.
  • X 2 is —(NR 2 )—.
  • X 3 is —S—.
  • X 3 is —O—.
  • X 3 is —(NR 2 )—.
  • R 2 is H.
  • R 2 is methyl
  • R 2 is ethyl
  • R 3 is, independently, H, methyl, or ethyl.
  • R 3 is H.
  • R 3 is methyl
  • R 3 is ethyl
  • R 1 and the ⁇ -carboxylate when taken together, form a lactone having 4 to 7 ring atoms, preferably a 4- to 7-membered ring lactone.
  • the lactone would undergo hydrolysis in vivo to release the active form of the arginase inhibitor.
  • the HMG-CoA reductase inhibitor lovastatin contains a 6-membered ring lactone that undergoes hydrolysis at gastric pH and temperature (half-life of about 1 hour) to form the pharmacologically active hydroxy acid. See, e.g., Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology, Testa and Mayer, Eds. Wiley Interscience (2003).
  • a lactone form is essentially a prodrug form of a compound of the invention.
  • R 1 may be a hydroxyalkenyl and, together with the ⁇ -carboxylate, can form a cyclic lactone, preferably 6- and 7-membered rings, and the double bond can be part of an aromatic ring, as shown below in FIGS. 1-2 .
  • This substitution can be made at any position on the aromatic ring; substitutions at ortho or para positions relative to the phenolic oxygen would allow for direct resonance effects with certain M groups (e.g., —NH 2 or —NO 2 ) to modulate the reactivity of the ester linkage.
  • M groups e.g., —NH 2 or —NO 2
  • the skeleton of the bicyclic ring system is that of dihydro-coumarin.
  • Unsubstituted dihydrocoumarin has a half-life of about 1 hour at 37° C. in the stomach, so the hydrolysis of the dihydrocoumarin in vivo will release the active form of the arginase inhibitor on a therapeutically-relevant timescale.
  • Preparation of 3-substituted and 3,3-disubstituted dihydrocoumarin derivatives may be prepared by conventional techniques, such as those disclosed in Murakata et al., Chem. Pharm. Bull 47, 1380-83 (1999), which is incorporated herein by reference.
  • the cyclic lactone prodrugs may also be prepared in accordance with the general syntheses described in U.S. Pat. No. 3,161,655 (Dec. 15, 1964), such as Example 11 thereof, which is incorporated herein by reference.
  • compositions comprising:
  • compositions comprising:
  • At least one pharmaceutically acceptable carrier at least one pharmaceutically acceptable carrier.
  • the compound or pharmaceutically acceptable salt thereof will be present in an effective amount.
  • the compound or a pharmaceutically acceptable salt thereof will be present at a level of from about 0.1%, by weight, to about 90% by weight, based on the total weight of the pharmaceutical composition.
  • the compound or a pharmaceutically acceptable salt thereof will be present at a level of at least about 1%, by weight, based on the total weight of the pharmaceutical composition.
  • the compound or a pharmaceutically acceptable salt thereof will be present at a level of at least about 5%, by weight, based on the total weight of the pharmaceutical composition.
  • the compound or a pharmaceutically acceptable salt thereof will be present at a level of at least about 10%, by weight, based on the total weight of the pharmaceutical composition.
  • the compound or a pharmaceutically acceptable salt thereof will be present at a level of at least about 25%, by weight, based on the total weight of the pharmaceutical composition.
  • Embodiments of the invention also include combination therapies, which include coadministration of an arginase inhibitor hereof with another medicine.
  • combination therapy refers to the administration of two or more therapeutic agents or compounds to treat a therapeutic condition or disorder described in the present disclosure. Such administration includes use of each type of therapeutic agent in a concurrent or simultaneous manner. Such administration includes the use of each type of therapeutic agent in the same unit dosage form or in separate unite dosage forms. In either case, the treatment regimen will provide beneficial effects of the drug combination in treating the conditions or disorders described herein.
  • compositions comprising:
  • PDE1 phosphodiesterase-1
  • PDE2 phosphodiesterase-2
  • PDE5 phosphodiesterase-5
  • arginase inhibitors of the invention are useful in the treatment of patients who do not respond to PDE5 inhibitors because arginase operates at an earlier stage in the pathway leading to NO-dependent relaxation of genital smooth muscle tissue required for sexual arousal.
  • Suitable phosphodiesterase-1 (PDE1) inhibitors include 5E3623 (available from Eisai), BAY 383045 (available from Bayer), HFV 1017 (7-benzenesulfonylamino-3a-ethyl-1,2,3,3a,10,11b-hexahydro-11H-5a,11a-diaza-benzo[cd]fluoranthene-5-carboxylic acid ethyl ester 2,3-dihydroxy-succinate available from Daiichi Fine Chemical), KF 19514 (5-phenyl-3-(3-pyridil) methyl-3H-imidazo[4,5-c][1,8]naphthyridin-4(5H)-one available from Kyowa Hakko) and SCH 51866 ((cis-5,6a,7,8,9,9a-hexahydro-2-[4-(trifluoromethyl)phenylmethyl]-5-methyl-cyclopent[4,5]imidazo[2,
  • Suitable phosphodiesterase-2 (PDE2) inhibitors include BAY 607550 (2-(3,4-Dimethoxy-benzyl)-7-[1-(1-hydroxy-ethyl)-4-phenyl-butyl]-5-methyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one available from Bayer).
  • Suitable phosphodiesterase-5 (PDE5) inhibitors include sildenafil (sold under the tradename ViagraTM), vardenafil (sold under the tradename LevitraTM), tadalafil (sold under the tradename ClalisTM), mirodenafil, udenafil, avanafil, dasantafil, NM 702 (4-bromo-6-[3-(4-chloro-phenyl)-propoxy]-5-[(pyridin-3-ylmethyl)-amino]-2H-pyridazin-3-one hydrochloride available from Nissan Chemical Industries), SLx-2101 (available for Surface Logix) and UK 369003 (available from Pfizer).
  • Suitable non-specific PDE inhibitors that inhibit PDE1, PDE2, PDE5, or a combination thereof include amlexanox, caffeine citrate, doxofylline, levosimendan, mopidamol, pentoxifylline, pemobendan, propentofylline, vesnarinone, and ibudilast.
  • compositions are prepared in accordance with acceptable pharmaceutical procedures, such as described in Remington's Pharmaceutical Sciences, 17th edition, ed. Alfonoso R. Gennaro, Mack Publishing Company, Easton, Pa. (1985).
  • Pharmaceutically acceptable carriers are those that are compatible with the other ingredients in the formulation and biologically acceptable.
  • compounds of the invention may be administered orally or parenterally, neat or in combination with conventional pharmaceutical carriers.
  • Applicable solid carriers can include one or more substances that may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents or an encapsulating material.
  • the carrier is a finely divided solid that is in admixture with the finely divided active ingredient.
  • the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired.
  • the powders and tablets preferably contain up to 99% of the active ingredient.
  • Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes, and ion exchange resins.
  • Liquid carriers may be used in preparing solutions, suspensions, emulsions, syrups, and elixirs.
  • the active ingredient of this invention can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic solvent, a mixture of both or pharmaceutically acceptable oils or fat.
  • the liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers, or osmo-regulators.
  • liquid carriers for oral and parenteral administration include water (particularly containing additives as above, e.g., cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g., glycols) and their derivatives, and oils (e.g., fractionated coconut oil and arachis oil).
  • the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate.
  • Sterile liquid carriers are used in sterile liquid form compositions for parenteral administration.
  • Liquid pharmaceutical compositions which are sterile solutions or suspensions, can be administered by, for example, intramuscular, intraperitoneal, or subcutaneous injection. Sterile solutions can also be administered intravenously. Oral administration may be either liquid or solid composition form.
  • the pharmaceutical composition is in unit dosage form, e.g., as tablets, capsules, powders, solutions, suspensions, emulsions, granules, or suppositories.
  • the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient;
  • the unit dosage forms can be packaged compositions, for example packeted powders, vials, ampoules, prefilled syringes or sachets containing liquids.
  • the unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.
  • the compounds useful in the present invention may be coadministered to a mammal with one or more other pharmaceutical active agents such as those agents being used to treat any other medical condition present in the mammal.
  • pharmaceutical active agents useful for such combination therapies include pain relieving agents, anti-angiogenic agents, anti-neoplastic agents, anti-diabetic agents, anti-infective agents, or gastrointestinal agents, or combinations thereof.
  • the one or more other pharmaceutical active agents may be administered in a therapeutically effective amount simultaneously (such as individually at the same time, or together in a pharmaceutical composition), or successively with one or more compounds of the present invention.
  • the route of administration may be any route, which effectively transports the active compound of the invention to the appropriate or desired site of action, such as oral, nasal, pulmonary, transdermal, such as passive or iontophoretic delivery, or parenteral, e.g., rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment.
  • parenteral e.g., rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment.
  • the administration of compound of formula Ia or formula Ib with other active ingredients may be concurrent or simultaneous.
  • Dosage unit form refers to physically discrete units suited as unitary dosages for the patient to be treated; each unit containing a predetermined quantity of the peptide calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
  • the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and the limitations inherent in the art of compounding such an active compound for the treatment of the patients.
  • compositions can be included in a container, pack, or dispenser together with instructions for administration.
  • dosages of the compounds of the invention that can be administered to an animal range in amount from 1 microgram to about 100 milligrams per kilogram of body weight of the animal.
  • the precise dosage administered will vary depending upon any number of factors, including but not limited to, the type of animal and type of disorder being treated, the age of the animal and the route of administration.
  • the dosage of the compound will vary from about 10 micrograms to about 10 milligrams per kilogram of body weight of the animal. More preferably, the dosage will vary from about 100 micrograms to about 5 milligrams per kilogram of body weight of the animal.
  • the compounds of the invention can be administered as needed or as directed by a health care provider to an animal as frequently as several times daily (e.g., once, twice, or thice daily), or it can be administered less frequently, such as once a day, once a week, once every two weeks, once a month, or even less frequently, such as once every several months or even once a year or less.
  • the frequency of the dose will be readily apparent to the skilled artisan and will depend upon any number of factors, such as, but not limited to, the type and severity of the disorder being treated, the type and age of the animal, etc.
  • Diagnostic medical imaging has become a critical element of modern health care. Ultrasound, radionuclide, X-ray, and magnetic resonance imaging techniques facilitate the diagnosis of disease. Diagnostic pharmaceuticals, frequently called contrast agents, may be administered to a patient in place of a therapeutic arginase inhibitors, or they may be simultaneously administered with a therapeutic agent to a patient to augment the usefulness of the imaging technique itself. Such imaging agents act by altering the energy or the way that energy interacts with tissues. Diagnostic medical imaging frequently uses targeted contrast agents that, in binding or localizing at sites selectively within the body, help to resolve an image of diagnostic interest.
  • Targeted diagnostic imaging contrast agents generally consist of a targeting moiety labeled with a traceable imaging moiety.
  • traceable imaging moieties include fluorescent tags; radio-opaque dyes (e.g., iodinated aromatics), radioactive elements such as 3 H, 18 F, 125 I, 129 I; or diagnostically useful chelated radioactive or paramagnetic metals such as Gd(III), Mn(II), Tc-99m, Re-186, Re-188, In-111, or Ga-67.
  • useful diagnostic imaging agents of the invention include compounds according to formulas IA, IB, Ia, and Ib, wherein at least one hydrogen atom of the R 1 group has been substituted with one of the foregoing imaging moieties.
  • the targeting moiety carries the label to the site of diagnostic interest where it is detected, e.g., by MRI, US, CT, or radionuclide imaging (including SPECT and PET).
  • Y is a residue of an imageable moiety selected from the group consisting of a gamma ray emitting radioisotope, a positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
  • arginase inhibitor suitable conjugated to an imageable moiety By using such an arginase inhibitor suitable conjugated to an imageable moiety, endogenous arginase activity may be visually observed in a patient's body in real time.
  • the imageable moiety should not significantly interfere with the binding of the derivatized arginase inhibitor to its substrate.
  • arginase-inhibitor imageable-moiety conjugate will generally have a K i or less than about 1000 nM.
  • R 1 is a fluorescently-labeled derivative thereof.
  • a spectroscopic probe such as a fluorescent moiety or an NMR or MRI sensitive moiety or complex is covalently attached as the R 1 group through a flexible linker sufficiently long so that the probe does not make unfavorable interactions with the protein surface.
  • spectroscopic probe would be a useful diagnostic tool for noninvasive determination of arginase overexpression, as observed in certain disease states, such as, for example, asthma (overexpression of airway arginase), cancer (overexpression of arginase in certain breast cancers, colon cancers, and the like), or certain internal bacterial infections (e.g., H. pylori overexpresses bacterial arginase in order to evade the immune response in human stomach ulcers).
  • the invention is directed to methods of diagnosing arginase overexpression in a patient, comprising the step of:
  • R 1 is a labeled derivative thereof
  • the arginase overexpression is associated with asthma, cancer, bacterial infections, or combinations thereof.
  • the invention is directed to methods of diagnosing arginase overexpression in a patient, comprising the step of:
  • the arginase overexpression is associated with asthma, cancer, bacterial infections, or combinations thereof.
  • the invention is directed to methods for radioimaging a patient, comprising the steps of:
  • Y is an imageable moiety
  • the invention is directed to methods of inhibiting arginase, comprising the step of:
  • the arginase is yeast, bacterial, parasitic, or mammalian.
  • mammalian arginase is a human type I arginase or a human type II arginase (e.g., human penile arginase).
  • the invention is directed to diagnostic compositions, comprising:
  • R 1 is a labeled derivative thereof.
  • the invention is directed to diagnostic compositions, comprising:
  • the invention is based upon the discovery of compounds that inhibit the enzymatic activity of arginase. These compounds, which were not previously known to inhibit this enzyme (and not previously known to have any use), are useful for a variety of applications in medicine and research.
  • the compounds, compositions, and methods of the invention are useful for inhibiting the activity of arginase including, but not limited to, mammalian (e.g., human), yeast, and bacteria (such as H. pylori ) arginase.
  • the compounds, compositions, and methods described herein can be used to inhibit arginase activity in vitro or in vivo, for example, in a human.
  • These compositions can also be used to treat a disorder characterized either by abnormally high arginase activity in a tissue of a mammal or by abnormally low nitric oxide synthase activity in a tissue of the mammal, preferably a human.
  • “Inhibition” of arginase by an arginase inhibitor means reduction in the level of arginase activity in the presence of the inhibitor, compared with the level of arginase activity in the absence of the inhibitor.
  • arginase-linked diseases There are a large number of arginase-linked diseases, some of which are listed below. They are linked with the one, two, or all of the three phenomena related to constitutive or upregulated arginase activity described above. Many of these diseases are characterized by two or even three of the phenomena simultaneously or sequentially, e.g., cellular proliferation and accumulation of fibrotic tissue can stiffen airway or vascular tissue in a constricted state so that it is more difficult to achieve NO-dependent relaxation. Accordingly, the compounds of the invention may be used to treat conditions associated with abnormally high level of arginase activity or abnormally low level of NO synthase activity.
  • An “abnormally high level of arginase activity,” as used herein, means a level of arginase activity that exceeds the level found in normal tissue when the normal tissue does not exhibit an arginase related disorder phenotype.
  • An “abnormally low level of NO synthase activity,” as used herein, means a level of NO synthase activity which is lower than that found in normal tissue when the normal tissue does not exhibit an NO synthase related disorder phenotype.
  • the arginase inhibitors disclosed herein may be useful in the treatment, prevention, management, or diagnosis of one or more of the following diseases, conditions, or maladies, each of which is discussed individually below: (1) gastrointestinal diseases, (2) pulmonary inflammatory diseases, (3) sexual arousal disorders, (4) cardiovascular disorders, (5) diseases caused by a pathogenic microorganisms, (6) immunological disorders, (7) cancer, (8) pre-term labor, (9) Reynaud's disease, (10) psoriasis, (11) rheumatoid arthritis, and (12) Peyronie's Disease, among others. Each of these conditions is discussed below.
  • An increase in arginase activity has been associated with the pathophysiology of a number of conditions including impairment in non-adrenergic and non-cholinergic (NANC) nerve-mediated relaxation of gastrointestinal smooth muscle.
  • NANC non-adrenergic and non-cholinergic
  • An arginase inhibitor can be used to alleviate such impairment by administering the inhibitor to a mammal experiencing such impairment or a mammal which is anticipated to experience such impairment (e.g., a human afflicted with a gastrointestinal motility disorder).
  • the compounds of the invention may be useful in the treatment or prevention of gastrointestinalmotility disorders, which is based on the observation that arginase is present in opossum internal anal sphincter muscle and the known arginase inhibitor, ABH, has been shown to relax this muscle. See, e.g., Baggio et al., J. Pharm. Exp. Ther. 290, 1409-16 (1999).
  • the compounds of the invention may also be useful in the treatment or prevention of inflammatory bowel disease (e.g., Crohn's disease and ulcerative colitis).
  • IBD has been shown to be characterized by increased arginase activity and endothelial dysfunction. See, e.g., Horowitz et al., Am. J. Physiol. Gastrointest. Liver Physiol. 292, G1323-36 (2007).
  • the compounds of the invention may be useful in the treatment or prevention of gastric ulcers, because the bacterium that causes stomach ulcers, Helicobacter pylori , exhibits increased arginase activity upon colonization in order to evade the human immune response. See, e.g., Gobert et al., Proc. Natl. Acad. Sci. (USA) 98, 13844-49 (2001).
  • the compounds of the invention may be useful in the treatment or prevention of asthma based on the observation that arginase is upregulated in the asthmatic airway. See, e.g., Zimmermann and Rothenberg, Eur. J. Pharmacol. 533, 253-62 (2006). Furthermore, nebulizer treatment of guinea pigs with ABH in an allergic asthma model prevents airway hyperresponsiveness. See, e.g., Maarsingh, “Arginase: A Novel Key Enzyme in the Pathophysiology of Allergic Asthma,” Ph.D. dissertation, Chapter 9, University of Groningen, Netherlands (2006); Maarsingh et al., Am. J. Respir. Crit. Care Med. 178, 565-73 (2008).
  • the asthma phenotype is characterized by airway constriction, airway smooth muscle hyperplasia, and the chronic accumulation of fibrotic tissue; an arginase inhibitor can relax airway smooth muscle and attenuate cellular hyperplasia and fibrosis.
  • the compounds of the invention may be useful in the treatment or prevention of chemically-induced lung fibrosis because arginase I and II are induced in bleomycin-induced lung fibrosis in order to provide more L-ornithine for collagen biosynthesis. See, e.g., Endo et al., Am. J. Physiol. Lung Cell Mol. Physiol. 285, L313-21 (2003).
  • the compounds of the invention may also be useful in the treatment or prevention of idiopathic pulmonary fibrosis, based on the observation that virus-induced upregulation of arginase I is observed in an animal model. See, e.g., Mora et al., Am. J. Respir. Cell Mol. Biol. 35, 466-73 (2006).
  • the compounds of the invention may be useful in the treatment or prevention of cystic fibrosis.
  • Increased sputum arginase activity contributes to NO deficiency in cystic fibrosis lung disease; arginase activity also contributes to fibrosis. See, e.g., Graseman et al., Am. J. Respir. Crit. Care Med. 172, 1523-28 (2005).
  • Erectile dysfunction afflicts one-half of the male population over the age of forty. This malady often results from defects in the complex cascade of enzyme-catalyzed reactions governing blood flow into and out of the corpus cavernosum, a chamber of muscular, spongy tissue that becomes engorged with blood in the erect penis. Defects that compromise cavernosal blood flow often occur as secondary complications related to other health conditions, such as heart disease, hypertension, diabetes, use of certain medications, and the like.
  • the invention relates to use of an arginase inhibitor described herein for enhancing penile erectile function in a mammal (preferably a male human) or for alleviating erectile dysfunction in a mammal.
  • NO is an important regulator of erectile function and mediates NANC neurotransmission in penile corpus cavernosum smooth muscle, leading to rapid relaxation, which in turn leads to erection.
  • NO synthase which catalyzes oxidation of L-arginine to form L-citrulline and NO, is for this reason a key enzyme in penile smooth muscle physiology.
  • Arginase catalyzes hydrolysis of L-arginine to form L-ornithine and urea.
  • Arginase regulates NO synthase activity by affecting the amount of L-arginine available for oxidation catalyzed by NO synthase activity.
  • inhibition of arginase activity can enhance NO synthase activity, thereby enhancing NO-dependent smooth muscle relaxation in the corpus cavernosum and enhancing penile erection.
  • Arginase is present in rabbit and human penile corpus cavernosum and ABH enhances the NO-dependent relaxation of this tissue. See, e.g., Cox et al., Nature Struct. Biol. 6, 1043-47 (1999).
  • the arginase inhibitor, ABH enhances the erectile response in live male rabbits. See, e.g., Cama et al., Biochemistry 42, 8445-51 (2003).
  • Arginase II is upregulated in the corpus cavernosum of the diabetic man, resulting in reduced NO biosynthesis which, in turn, leads to erectile dysfunction; administration of ABH in ex vivo experiments restores NO biosynthesis.
  • Arginase I is upregulated in the penis of aged mice and impairs erectile function. See, e.g., Bivalacqua et al., Am. J. Physiol. Heart Circ. Physiol. 292, H1340-51 (2007).
  • the compounds of the invention may also be useful in the treatment or prevention of female sexual arousal disorder.
  • the arginase inhibitor, ABH enhances the engorgement response in the genitalia of live female rabbits. See, e.g., Cama et al., Biochemistry 42, 8445-51 (2003).
  • the compounds of the invention may be useful in the treatment or prevention of endothelial vascular dysfunction in atherosclerosis, hypertension, hypercholesterolemia, and diabetes.
  • Arginase modulates NOS activity by regulation of L-arginine availability, and the deleterious effects of arginase can be blocked by an arginase inhibitor. See, e.g., Berkowitz et al., Circulation 108, 2000-06 (2003); Yang and Ming, Clin. Med. Res. 4, 53-65 (2006).
  • Increased arginase activity in diabetes contributes to vascular endothelial dysfunction by decreasing L-arginine availability to NO synthase. See, e.g., Romero et al., Circ. Res. 102, 95-102 (2008).
  • Arginase inhibition attenuates hypertension in spontaneously hypertensive rats. See, e.g., Demougeot et al., J. Hypertens. 23, 971-78 (2005). Other relevant conditions include ischemia-reperfusion injury, peripheral vascular disease (PVD), peripheral arteial disease (PAD), and subarachnoid hemorrhage. Arginase has been identified as a new drug target for the treatment of atherosclerosis. See, e.g., Yang and Ming, Curr. Hypertension Rep. 8, 54-59 (2006).
  • the compounds of the invention may be useful in the treatment or prevention of pulmonary arterial hypertension. Elevated arginase activity contributes to vascular endothelial dysfunction by compromising L-arginine availability to NO synthase. See, e.g., Morris et al., Adv. Pulmonary Hypertension 5, 31-36 (2007).
  • the compounds of the invention may be useful in the treatment or prevention of African sleeping sickness, Chagas' disease, leishmaniasis, malaria, and other diseases caused by pathogenic microorganisms.
  • Polyamine biosynthetic enzymes are essential for growth and survival of protozoa. See, e.g., Heby et al., Biochem. Soc. Trans. 31, 415-19 (2003).
  • Arginase is essential for viability. See, e.g., Roberts et al., J. Biol. Chem. 279, 23668-78 (2004). Therefore, inhibitors of protozoan arginases can kill the protozoa.
  • D-arginase also known as guanidinobutyrase
  • D-arginase also known as guanidinobutyrase
  • the compounds of formula IA and IB would also be suitable as antibacterial agents because they are expected to exhibit antibacterial properties, e.g., against guanidinobutyrase of Pseudomonas aeruginosa . See, Nakada and Itoh, J. Bacteriol. 184, 3377-84 (2002).
  • Arginase can be inhibited in yeast by contacting the yeast with the composition of the invention Inhibition of arginase in yeast serves to minimize urea production during fermentation of alcoholic beverages.
  • the compounds of the invention may be useful in the treatment or prevention of multiple sclerosis, and possibly other autoimmune diseases, based upon the observation that arginase I is upregulated in an animal model of multiple sclerosis (experimental autoimmune encephalomyelitis) and administration of the arginase inhibitor ABH improves the disease score of animals. See, e.g., Xu et al., Immunology 110, 141-48 (2003).
  • T-cell tolerance Impairs the therapeutic efficacy of immunotherapy; one mechanism leading to T-cell tolerance is the generation of myeloid-derived suppressor cells (MDSCs), which produce arginase, thereby depleting the tumor microenvironment of L-arginine, which impairs T-cell signal transduction and function. T-cell anergy results.
  • MDSCs myeloid-derived suppressor cells
  • arginase activity is a mechanism of immune system evasion that is also shared by certain bacteria, e.g., Helicobacter pylori .
  • MDSCs are regarded as “cancer's bulwark against immune attack.” See, e.g., Marx, Science 319, 154-56 (2008).
  • arginase is upregulated in the following types of cancers, which may be treated with an arginase inhibitor described herein: Renal cell carcinoma (see, e.g., Zea et al., Cancer Res. 65, 3044-48 (2005); Ochoa et al., Clin. Cancer Res. 13, 721s-26s (2007)); prostate cancer (see, e.g., Bronte et al., J. Exp. Med. 201, 1257-68 (2005) (arginase inhibition with N-hydroxy-L-arginine facilitates tumor immunotherapy); colorectal cancer (see, e.g., Leu and Wang, Cancer 70, 733-36 (1992); Bronte and Zanovello, Nature Rev. Immunol.
  • Renal cell carcinoma see, e.g., Zea et al., Cancer Res. 65, 3044-48 (2005); Ochoa et al., Clin. Cancer Res. 13, 721s-26s (2007)
  • prostate cancer see, e
  • breast cancer see, e.g., Singh et al., Cancer Res. 60, 3305-12 (2000); Bronte and Zanovello, Nature Rev. Immunol. 5, 641-54 (2005) (the arginase inhibitor, N-hydroxy-L-arginine, inhibits cell proliferation and induces apoptosis)); skin cancer (squamous cell and basal cell cancers) (see, e.g., Gokmen et al., J. Lab. Clin. Med. 137, 340-44 (2001); Bronte and Zanovello, Nature Rev. Immunol. 5, 641-54 (2005)); lung cancer (see, e.g., Rodriguez et al., J. Exp. Med.
  • ovarian cancer see, e.g., Melichar et al., J. Translational Med. 1, 1-5 (2003) (doi:10.11861479-5876-1-5)); and gastric cancer (see, e.g., Wu et al., Life Sci. 51, 1355-61 (1992)); among others.
  • Enhancement of uterine smooth muscle relaxation with an arginase inhibitor may be useful in the management of pre-term labor.
  • Reynaud's disease is a disease of the microvasculature. Because subcutaneous administration of the arginase inhibitor BEC (which is an analogue of ABH) in humans is vasodilatory and enhances circulation, an arginase inhibitor may be useful in treating Reynaud's disease. See, e.g., Holowatz et al., J. Physiol. 574, 573-81 (2006).
  • Arginase I is highly overexpressed in the hyperproliferative psoriatic epidermis in human skin, and therefore arginase inhibitors may be useful in the treatment of psoriasis. See, e.g., Bruch-Gerharz et al., Am. J. Pathology 162, 203-11 (2003).
  • Arginase II is upregulated in synovial fluid from human patients, and therefore arginase inhibitors may be useful in the treatment of arthritis. See, e.g., Huang et al., Kaohsiung J. Med. Sci. 17, 358-63 (2001); Corraliza and Moncada, J. Rheumatol. 29, 2261-65 (2002).
  • the compounds of the invention may be useful in the treatment or prevention of Peyronie's disease.
  • Arginase II is upregulated in the rat penis in an animal model for this disease. See, e.g., Bivalacqua et al., J. Andrology 22, 497-506 (2001). While this disorder can contribute to erectile dysfunction, it is principally an inflammatory condition in which fibrotic tissue builds up in the penis.
  • the composition of the invention can be used to treat a disorder in a mammal, wherein the disorder is associated with expression of an abnormally high level of arginase activity in a tissue of the mammal. Because NO synthase activity is regulated in a reciprocal fashion with respect to arginase activity in mammals, more particularly humans, the compounds and compositions of the invention can be used to treat a disorder in a mammal, wherein the disorder is associated with expression of an abnormally low level of NO synthase activity in a tissue of the mammal. Since the reciprocal interaction of arginase and NO synthase has implications for the function of smooth muscle, the use of the compounds described herein for the regulation of smooth muscle activity in an animal is also contemplated in the invention.
  • a compound of the invention or a composition comprising the compound of the invention which comprises an arginase inhibitor described herein can also be used to inhibit arginase in a mammal having normal levels of arginase and NO synthase activity, particularly where the physiology which is desired to be effected is one which is affected by arginase or NO synthase activity, or where a disorder which is not caused by aberrant arginase or NO synthase activity levels can nonetheless be alleviated or inhibited by inhibiting arginase activity (e.g., certain forms of erectile dysfunction).
  • arginase activity e.g., certain forms of erectile dysfunction
  • the invention also includes a method of enhancing smooth muscle relaxation comprising contacting the smooth muscle with an arginase inhibitor.
  • the smooth muscle is preferably within the body of an animal.
  • the type of smooth muscle to be relaxed includes, but is not limited to, gastrointestinal smooth muscle, anal sphincter smooth muscle, esophageal sphincter muscle, sphincter of Oddi, arterial smooth muscle, heart smooth muscle, pulmonary smooth muscle, kidney smooth muscle, uterine smooth muscle, vaginal smooth muscle, cervical smooth muscle, placental smooth muscle, and ocular smooth muscle.
  • the type of gastrointestinal smooth muscle includes, but is not limited to, the internal anal sphincter muscle.
  • the invention includes a method of alleviating (e.g., reducing the incidence or severity) or inhibiting (e.g., reducing the likelihood of developing, or preventing) an arginase-related disorder in an animal.
  • the animal is a human.
  • an arginine inhibitor described herein is administered to a mammal afflicted with the disorder.
  • the inhibitor is preferably administered in combination with one or more pharmaceutically acceptable carriers, as described in further detail herein.
  • the inhibitor (preferably in combination with a carrier) can also be administered to a mammal afflicted with a disorder characterized by aberrant NO synthase activity, or to one which exhibits normal (i.e. non-diseased) levels of arginase and NO synthase activities, but in which inhibition of arginase activity is desired.
  • the invention also contemplates use of an arginase inhibitor in an in vitro arginase inhibition/smooth muscle relaxation functional assay, for the purpose of identifying compounds which affect smooth muscle function.
  • Compounds so identified are considered to be candidate arginase inhibitor antagonists, in that these compounds are identified by their ability to counteract the inhibition of arginase activity.
  • these compounds by be identified by using an assay for smooth muscle activity using the internal anal sphincter muscle and one on the arginase inhibitors of the invention.
  • strips of the internal anal sphincter muscle obtained from a mammal are induced to relax by NANC nerve-mediated relaxation using electrical field stimulation (EFS); relaxation is reversed by contacting the muscle strips with arginase; and reversal of relaxation is accomplished by contacting the muscle with an arginase inhibitor.
  • EFS electrical field stimulation
  • the muscle strips are then subsequently contacted with a test compound. The effect of the test compound on subsequent reversal of muscle relaxation is assessed. Any significant reversal of the relaxation state of the muscle in the presence of the test compound, compared with the relaxation state of the muscle in the absence of the test compound, is an indication that the test compound is an arginase inhibitor antagonist.
  • the invention is directed to methods of inhibiting arginase in a mammal, comprising the step of:
  • the invention is directed to methods of treating an arginase-related disorder in a mammal, comprising the step of:
  • the arginase-related disorder is a disorder associated with an abnormally low level of nitric oxide synthase activity in a tissue of the human, a disorder associated with an abnormally high level of arginase activity in a tissue of the human, or combinations thereof, including heart disease, systemic hypertension, pulmonary hypertension, erectile dysfunction, autoimmune encephalomyelitis, chronic renal failure, gastrointestinal motility disorders, gastric cancers, reduced hepatic blood flow, insufficient hepatic blood flow, cerebral vasospasm, or a combination thereof.
  • the invention is directed to methods of relaxing smooth muscle in a mammal, comprising the step of:
  • the smooth muscle which is relaxed according to this method is at least one selected from the group consisting of a gastrointestinal smooth muscle, anal sphincter smooth muscle, esophageal sphincter muscle, corpus cavernosum, sphincter of Oddi, arterial smooth muscle, heart smooth muscle, pulmonary smooth muscle, kidney smooth muscle, uterine smooth muscle, vaginal smooth muscle, cervical smooth muscle, placental smooth muscle, and ocular smooth muscle.
  • the invention is directed to methods of treating a disease or condition associated with upregulation of arginase in a mammal, comprising the step of:
  • said disease or condition is a gastrointestinal disease, a pulmonary inflammatory disease, a sexual arousal disorder, a cardiovascular disorder, a hemolytic disorder, an autoimmune disease, wound healing, a disease caused by parasitic protozoa, a disease caused by bacteria, a cancer, pre-term labor, psoriasis, or a combination thereof.
  • Inhibiting arginase impacts cancer in two ways.
  • the first way is relief from immune-suppression that leads to tolerance of the tumor and the second way is by restricting the production of ornithine and subsequent polyamines, which have a role in proliferation.
  • the gastrointestinal disease is a gastrointestinal motility disorder, inflammatory bowel disease, Crohn's disease, ulcerative colitis, gastric ulcer, adenotonsilar disease or a combination thereof.
  • the pulmonary inflammatory disease is asthma, chemically-induced lung fibrosis, idiopathic pulmonary fibrosis, cystic fibrosis, chronic obstructive pulmonary disease (COPD) or a combination thereof.
  • COPD chronic obstructive pulmonary disease
  • the sexual arousal disorder is male erectile dysfunction, Peyronie's Disease, or a female sexual arousal disorder.
  • the cardiovascular disorder is endothelial vascular dysfunction in atherosclerosis, hypertension, ischemia reperfusion injury, peripheral vascular disease, peripheral arterial disease, subarachnoid hemorrhage, hypercholesterolemia, diabetes, or a combination thereof, diabetic cardiovascular disease, pulmonary arterial hypertension, Reynaud's disease, or a combination thereof.
  • the hemolytic disorder is paroxysmal nocturnal hemoglobinuria (PNH), sickle-cell disease, thalassemias, hereditary spherocytosis and stomatocytosis, microangiopathic hemolytic anemias, pyruvate kinase deficiency, ABO mismatch transfusion reaction, paroxysmal cold hemoglobinuria, severe idiopathic autoimmune hemolytic anemia, infection-induced anemia, malaria, cardiopulmonary bypass, mechanical heart valve-induced anemia, chemical induced anemia, or a combination thereof.
  • PNH paroxysmal nocturnal hemoglobinuria
  • sickle-cell disease thalassemias
  • hereditary spherocytosis and stomatocytosis microangiopathic hemolytic anemias
  • pyruvate kinase deficiency pyruvate kinase deficiency
  • ABO mismatch transfusion reaction paroxysmal cold hemoglobinuria
  • the autoimmune disease is encephalomyelitis, multiple sclerosis, anti-phospholipid syndrome 1, autoimmune hemolytic anaemia, chronic inflammatory demyelinating polyradiculoneuropathy, dermatitis herpetiformis (“Celiac Disease”), dermatomyositis, myasthenia gravis, pemphigus, rheumatoid arthritis, stiff-person syndrome, type 1 diabetes, ankylosing spondylitis, or a combination thereof.
  • the condition is wound healing.
  • the disease caused by parasitic protozoa is African sleeping sickness, Chagas' disease, leishmaniasis, malaria, or a combination thereof.
  • the cancer is renal cell carcinoma, prostate cancer, colorectal cancer, breast cancer, skin cancer, lung cancer, ovarian cancer, gastric cancer, or a combination thereof.
  • the skin cancer is a squamous cell cancer, basal cell cancer, or a combination thereof.
  • the condition is pre-term labor.
  • the condition is Reynaud's disease.
  • the invention is directed to methods of providing relief from immune suppression in a mammal, comprising the step of:
  • said mammal is suffering from a disease or condition selected from the group consisting of a chronic infectious disease, a bacterial infection, a parasitic infection, trauma, leprosy, tuberculosis, liver transplantation, a cancer, and combinations thereof.
  • a disease or condition selected from the group consisting of a chronic infectious disease, a bacterial infection, a parasitic infection, trauma, leprosy, tuberculosis, liver transplantation, a cancer, and combinations thereof.
  • the invention is directed to methods of inhibiting the production of ornithine in a mammal suffering from at least one tumor, comprising the step of:
  • the compounds and compositions of the invention are useful as anti-fungicides in agriculturally or otherwise economically important plant life.
  • the compounds and compositions of the invention can be therapeutically administered to a plant by spraying or other means well known in the art of plant biology.
  • the compounds of the present invention may be prepared in a number of ways well known to those skilled in the art.
  • the compounds can be synthesized, for example, by the methods described below, or variations thereon as appreciated by the skilled artisan. Variables used are as defined for formula Ia or formula Ib, unless otherwise noted.
  • the reagents used in the preparation of the compounds of this invention can be either commercially obtained or can be prepared by standard procedures described in the literature. All processes disclosed in association with the present invention are contemplated to be practiced on any scale, including milligram, gram, multigram, kilogram, multikilogram or commercial industrial scale.
  • the compounds of formula IA or formula IB containing a double bond between X 3 and X 4 may be prepared in accordance with the synthetic scheme set forth in Collet, et al. (2000) J. Chem. Soc., Perkin Trans. 1, 177-182, which is incorporated herein by reference in its entirety, with the appropriately substituted R 1 group.
  • FIG. 3 schematically illustrates the solid-phase synthesis of compounds 1 of the present invention, where R 1 is generated from reagents that are “activated” alkyl halides, such as benzyl bromide.
  • R 1 is generated from reagents that are “activated” alkyl halides, such as benzyl bromide.
  • the Fmoc group of Fmoc-Gly-Wang resin is removed by methods well known in the art. Atherton and Sheppard, “The Fluorenylmethoxycarbonyl Amino Protecting Group,” in The Peptides, Udenfriend and Meienhofer, Eds., Academic Press, New York (1987), vol. 9, p. 1).
  • the amine is protected as the N-diphenylmethylene amine by treating the resin-bound free amine with excess benzophenone imine and glacial acetic acid in NMP. See, O'Donnell et al., Tetrahedron Lett., 38, 7163 (1997) resulting in compound 3.
  • This protected glycine is reacted with excess 2-(4-bromobutyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (4a) in the presence of an organic non-nucleophilic base such as BEMP or BTPP in NMP resulting in compound 5.
  • the reaction can be accelerated by the addition of tetrabutylammonium iodide or even more preferred the alkylating reagent can be the iodo derivative instead of the bromo compound.
  • the second side chain can be introduced by treating 5 with a strong base such as n-BuLi, LDA, or the preferred base KHMDS under anhydrous conditions and then adding another alkyl halide, such as benzyl bromide resulting in compound 6. See, Griffith et al., Tetrahedron Lett. 38, 8821 (1997).
  • the desired amino acid (1, wherein R 1 may be of a number of sidechains as described herein) can be released from the resin by treating with strong aqueous acid at high temperature (not shown) or, alternatively, the controlled deprotection and release of compound 1 can be completed in a stepwise manner as illustrated in FIG. 3 .
  • FIG. 4 outlines an exemplary solid-phase synthesis of compound 1d of the present invention, where R 1 is generated from reagents that are “unactivated” alkyl halides such as bromoethane.
  • Compound 3 is reacted with excess alkyl halide in the presence of an organic non-nucleophilic base such as BEMP or BTPP in NMP resulting in compound 7.
  • the reaction can be accelerated by the addition of tetrabutylammonium iodide or even more preferred the alkylating reagent can be the iodo-derivative instead of the bromo-compound.
  • the second side chain can be introduced after the amine protecting group is switched from the ketimine to an aldimine as shown in FIG.
  • FIG. 5 outlines the solid-phase synthesis of some compounds of the present invention where R 1 is generated from reagents such as bromomethylpyridine that may be unstable to KHMDS or other very strong bases.
  • compound 5 is treated with mild aqueous acid followed by neutralization of the hydrochloride salt to produce 11.
  • This intermediate is protected as the aldimine 12, which is then treated with excess alkylating agent and BTPP in NMP to give intermediate 13 (Scott, W. L., Tetrahedron Lett. 1997, 38:3695).
  • the desired amino acid (1e) is released from the resin by treating with strong aqueous acid at high temperature (not shown) or, alternatively, the controlled deprotection and release of 1e can be done stepwise as shown in FIG. 5 .
  • the hydrochloride salt of a glycine alkyl ester 14a-c is reacted with benzophenone imine, O'Donnell, et al., J. Org. Chem. 47, 2663 (1982), at room temperature to give the corresponding ketimine protected glycine ester 16a-c.
  • This transimination is particularly useful for tent-butyl ester 16c.
  • alkyl esters of ⁇ -bromoacetic acid 15a-c can be reacted with benzophenone in refluxing acetonitrile as shown in the second reaction resulting in 16a-c. O'Donnell, Acc. Chem. Res. 37, 506 (2004).
  • FIG. 7 illustrates a solution-phase synthesis of compound 1 of the present invention where R 1 is generated from reagents that are “activated” alkyl halides, such as benzyl bromide.
  • R 1 is generated from reagents that are “activated” alkyl halides, such as benzyl bromide.
  • Compound 16 is reacted with LiHMDS at low temperature as described in Reddy et al., Org. Biomol. Chem. 5, 889 (2007), and then 1 equivalent of reagent 4b is added and allowed to react at room temperature for several hours to give intermediate compound 18.
  • the second side chain is introduced by treating compound 18 with a strong base such as n-BuLi, LDA, or the preferred base KHMDS under anhydrous conditions at low temperature and then adding another alkyl halide, such as benzyl bromide, resulting in compound 19.
  • Compound 19 is globally deprotected by treating with strong aqueous acid to give compound 1 (wherein R 1
  • FIG. 8 outlines an exemplary solution-phase synthesis of compound 1 of the present invention, where R 1 is generated from a variety of alkyl halides including poorly reactive reagents.
  • Compound 16 is reacted with LiHMDS at low temperature as described in Reddy et al., Org. Biomol. Chem. 5, 889 (2007), and then 1 equivalent of R 1 —X (wherein R 1 may be of a number of sidechains as described herein) is added and allowed to react at room temperature for several hours to give compound 20.
  • the second side chain (R 1 ) can be introduced by treating intermediate compound 20 with a strong base such as n-BuLi, LDA, or the preferred base KHMDS under anhydrous conditions at low temperature and then adding 1 equivalent of crotyl bromide to give compound 21.
  • Hydroboration of the crotyl side chain to give the boronate ester side chain is accomplished by treatment with pinacol borane in the presence of iridium catalyst similar to that reported by Yamamoto et al., Tetrahedron 60, 10695 (2004), to give compound 19, which is globally deprotected by treating with strong aqueous acid to give compound 1.
  • FIG. 9 illustrates an exemplary solution-phase synthesis of compound 1 of the present invention, where R 1 is generated from a set of alkyl halides such as ⁇ -haloacetate esters. Functionalities of this type provide intermediates with multiple sites of alkylation for the next reaction. Therefore, introduction of the crotyl side chain first is preferred for this compound class.
  • Compound 16 is treated with 1.5 eq of BTPP (or BEMP) and crotyl bromide at room temperature for several hours, O'Donnell, J. Acc. Chem. Res. 37, 506 (2004) to give compound 22.
  • the R 1 side chain can be introduced by treating compound 22 with a strong base such as n-BuLi, LDA, or the preferred base KHMDS under anhydrous conditions at low temperature and then adding 1 equivalent of R 1 —X to give compound 21.
  • Hydroboration of the crotyl side chain to give the boronate ester side chain is accomplished by treatment with pinacol borane in the presence of iridium catalyst similar to that reported by Yamamoto et al., Tetrahedron 60, 10695 (2004), to give compound 19, which is globally deprotected by treating with strong aqueous acid to give compound 1 (wherein R 1 may be of a number of sidechains as described herein).
  • FIG. 10 outlines an exemplary solution-phase synthesis of compound 1 of the present invention where R 1 is generated from commercially available amino acids or esters such as L-leucine-tert-butyl ester HCl.
  • R 1 is generated from commercially available amino acids or esters such as L-leucine-tert-butyl ester HCl.
  • Compound 20 is prepared from these commercially available amino esters as described in FIG. 6 .
  • the second side chain (R 1 ) can be introduced by treating compound 20 with a strong base such as n-BuLi, LDA, or the preferred base KHMDS under anhydrous conditions at low temperature and then adding 1 equivalent of crotyl bromide to give intermediate compound 21.
  • a strong base such as n-BuLi, LDA, or the preferred base KHMDS
  • Hydroboration of the crotyl side chain to give the boronate ester side chain is accomplished by treatment with pinacol borane in the presence of iridium catalyst similar to that reported by Yamamoto et al., Tetrahedron 60, 10695 (2004), to give compound 19, which is globally deprotected by treating with strong aqueous acid to give compound 1 (wherein R 1 may be of a number of sidechains as described herein).
  • R 1 —X reagents used in the synthetic chemistry of FIGS. 3-10 are not commercially available. In such cases, they were made, for example, by the exemplary reactions outlined in FIG. 11 , among other methods.
  • FIG. 11 illustrates the use of a phenol starting material, the synthesis could be readily adapted to other similar starting materials, such as piperidine, piperazine, and morpholine compounds.
  • compound 27 could also be any of a variety of homologous compounds.
  • compound 25 is prepared by reacting substituted or unsubstituted phenols with 3-bromo-1-propanol in the presence of a base, such as potassium carbonate, at elevated temperature for several hours. Upon isolation of product 25, it is converted to the alkyl iodide by reaction with iodine in the presence of imidazole and triphenylphosphine. Alternatively, resin-bound triphenylphosphine can also be used to give compound 25 that can be used in various alkylation steps as R 1 —X in accordance with the methods hereof.
  • a base such as potassium carbonate
  • amine-containing R 1 side chains can be introduced into compound 1 by preparing R 1 —X alkylating reagents such as compound 31 by first reacting starting material 26 with di-tent-butyl dicarbonate to give compound 27, which is subsequently O-protected by treating it with TBS-Cl and imidazole to give di-protected intermediate 28.
  • the base labile carbamate is further protected by another treatment with di-tert-butyl dicarbonate in the presence of dimethylaminopyridine to give tri-protected intermediate 29.
  • the TBS ether is removed by treating with fluoride ion in organic solvent to give alcohol 30.
  • alkyl iodide 31 is prepared in analogous manner as described above for the synthesis of compound 25.
  • FIG. 12 outlines the synthesis of exemplary compounds 38, 39, and 40 of the present invention where the R 1 sidechain is made by selective chemistry performed upon a primary amine and subsequent manipulation of this amine in R 1 .
  • compound 33 is generated by the methods outlined in FIGS. 8 and 11 . Anhydrous cleavage of the Boc protecting groups results in the primary amine 33. This primary amine can be capped with acyl groups by reacting with acid chlorides to give compound 34. Alternatively, compound 33 can be reacted with isocyanates in the presence of a tertiary amine to give urea 35.
  • compound 33 can be reacted with sulfonyl chlorides in the presence of a tertiary amine to give sulfonamide 36.
  • sulfonamide 36 can be further deprotected by a two-step process involving hydrolysis of the ketimine and then transesterification of the pinacol boronic ester by treating with an excess of phenyl boronic acid in a biphasic mixture to give final products 37-41.
  • FIG. 13 outlines the synthesis of N-alkylated compounds 63 and 64 in the present invention where R 1 includes a primary amine being converted to a secondary or tertiary amine.
  • R 1 includes a primary amine being converted to a secondary or tertiary amine.
  • This methology can also be used to prepare compounds with side chains containing a cyclic amine such as a piperidine or piperazine and the terminal amine is alkylated similarly.
  • Compound 33 from FIG. 12 can be treated with either one equivalent of an alkyl halide such as benzyl bromide to give compound 61 or alternatively it can be treated with two equivalents of an alkyl halide to give compound 62. Both of these compounds can be deprotected by any of the globally deprotecting procedures to give compounds 63 and 64, respectively, which are derivatives of compound 1.
  • This reaction scheme will also work for alkylating piperidine- and piperazine-containing compounds.
  • FIG. 14 outlines an exemplary asymmetric synthesis of ABH compound 1 in the present invention where R 1 is from a variety of alkyl halides.
  • Compound 41 is asymmetrically alkylated in the presence of 45 under phase transfer conditions resulting in 42 with the desired chirality in high % ee (enantiomeric excess) of >95%.
  • Conversion of imine 42 to acetate 43 results in an intermediate that can be hydroborated under conditions illustrated in FIG. 8 .
  • Compound 1 with the desired chirality is then produced by deprotection of all of the masking functionalities.
  • chiral compound 1 can be prepared by separating any disubstituted intermediate by chiral chromatography.
  • FIG. 15 illustrates an exemplary asymmetric synthesis of compound 1ar where R 1 side chain is specifically a CH 2 OH group.
  • Oxazoline 46 is prepared by acylating a serine derivative with an aryl acid chloride such as 2-naphthoic acid chloride, and then dehydrating the intermediate with DAST ((diethylamino)sulfur trifluoride).
  • DAST (diethylamino)sulfur trifluoride).
  • Compound 46 is alkylated by treating with crotyl bromide in the presence of a base, such as CsOH, to give chiral intermediate 47. This intermediate can be analyzed by chiral chromatography to ascertain the amount of enantiomeric enrichment.
  • Boronic ester 48 is introduced by the hydroboration process described above and the final product is isolated by strong acid cleavage of the protecting groups.
  • the racemic analog of compound 47 can be obtained by reaction of a strong base such as BTPP in the absence of chiral catalyst 45.
  • the desired enantiomer thereafter is be obtained by chiral chromatography.
  • FIG. 16 outlines the synthesis of nor NOHA compounds 47 in the present invention where R 1 is from a variety of alkyl halides.
  • Starting material 16c is preferred to avoid lactam formation during the synthesis of these compounds.
  • Compound 16c is treated with a base, e.g., LiHMDS, at low temperature under an argon atmosphere and the 1 equivalent of R 1 —X is added to give compound 20.
  • a strong base such as n-BuLi, LDA, or the preferred base KHMDS under anhydrous conditions at low temperature and then adding 1 equivalent of ⁇ -bromoacetonitrile to give 49.
  • the amine is deprotected and reprotected with a Boc group to give intermediate 50.
  • nitrile is reduced by catalytic hydrogenation using PtO 2 , Xue et al., J. Org. Chem. 60, 946 (1995), to give the primary amine 51.
  • This primary amine is transformed into the N-hydroxy guanidine group by the series of synthetic steps of cyanamide formation and reaction with hydroxylamine as reported by Custot et. al., J. Am. Chem. Soc. 119, 4086 (1997).
  • Deprotection to final product 54 proceeds by treatment with HCl/H 2 O.
  • FIG. 17 outlines the asymmetric synthesis of nor-NOHA compound 54 in the present invention where R 1 is from a variety of alkyl halides.
  • Compound 41 is asymmetrically alkylated in the presence of catalyst 45 under phase transfer conditions resulting in compound 55 with the desired chirality in high % ee (>95%). See, Ooi et al., J. Am. Chem. Soc. 122, 5228 (2000); and Jiang et al., Org. Proc. Res. Dev. 12, 1164 (2008).
  • Amine 55 is deprotected and reprotected with a Boc group to give compound 56.
  • Nitrile 56 is reduced by catalytic hydrogenation using PtO 2 , (Xue et al., J.
  • R 1 groups are presented in FIGS. 19-24 in the attached drawings. Using the synthetic chemistry methodology discussed herein above, the arginase inhibitors of the present invention having these and other R 1 sidechains made be readily prepared in accordance with these principles.
  • protecting groups may contain protecting groups during the course of synthesis.
  • Protecting groups are known per se as chemical functional groups that can be selectively appended to and removed from functionalities, such as hydroxyl groups and carboxyl groups. These groups are present in a chemical compound to render such functionality inert to chemical reaction conditions to which the compound is exposed. Any of a variety of protecting groups may be employed with the present invention.
  • Protecting groups that may be employed in accordance with the present invention may be described in Greene, T. W. and Wuts, P. G. M., Protective Groups in Organic Synthesis 2d. Ed., Wiley & Sons, 1991.
  • the compounds of this invention contain chiral centers, providing for various stereoisomeric forms such as diastereomeric mixtures, enantiomeric mixtures as well as optical isomers.
  • the individual optical isomers can be prepared directly through asymmetric or stereospecific synthesis or by conventional chiral separation of optical isomers from the enantiomeric mixture.
  • Some of the compounds of the present invention may contain chiral centers (beyond the C ⁇ ) and such compounds may exist in the form of stereoisomers (i.e. enantiomers).
  • the present invention includes all such stereoisomers and any mixtures thereof including racemic mixtures. Racemic mixtures of the stereoisomers as well as the substantially pure stereoisomers are within the scope of the invention.
  • Preferred enantiomers may be isolated from racemic mixtures by any method known to those skilled in the art, including high performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts or prepared by methods described herein. See, for example, Jacques, et al., Enantiomers, Racemates and Resolutions (Wiley Interscience, New York, 1981); Wilen, S. H., et al., Tetrahedron, 33:2725 (1977); Eliel, E. L. Stereochemistry of Carbon Compounds , (McGraw-Hill, NY, 1962); Wilen, S. H. Tables of Resolving Agents and Optical Resolutions , p. 268 (E. L. Eliel, Ed., University of Notre Dame Press, Notre Dame, Ind. 1972).
  • the present invention includes prodrugs of the compounds of formula Ia or formula Ib.
  • “Prodrug,” as used herein, means a compound which is convertible in vivo by metabolic means (e.g., by hydrolysis) to a compound of formula Ia or formula Ib.
  • Various forms of prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), Design of Prodrugs , Elsevier (1985); Widder, et al. (ed.), Methods in Enzymology , vol. 4, Academic Press (1985); Krogsgaard-Larsen et al., (ed).
  • the compounds of formula IA or formula IB may exist in unsolvated as well as in solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like.
  • the solvated forms are considered equivalent to the unsolvated forms for the purpose of the present invention.
  • glycine ethyl ester hydrochloride 14b (2.015 g, 14.4 mmol) was suspended in 25 mL dry DCM (dichloromethane) and benzophenone imine (2.42 mL, 14.4 mmol) was added and stirred at room temperature for 8-16 hr.
  • the reaction mixture was filtered, washed with 5 mL DCM and the organic solution was washed 1 ⁇ with H 2 O and 1 ⁇ with brine (a saturated aqueous solution of sodium chloride).
  • the DCM was dried by filtering over a bed of Hydromatrix brand diatomaceous earth and concentrating to dryness in vacuo.
  • compound 16 (1 mmol) was dissolved in 5 mL dry THF (tetrahydrofuran) under argon and cooled to ⁇ 78° C.
  • the reaction mixture was stirred at ⁇ 78° C. for 30 minutes and then allowed to warm to room temperature and stirred for 8-18 hr.
  • the desired product (compound 18) was isolated by diluting the reaction mixture with 20 mL EtOAc (ethyl acetate) and washing this organic solution with water and then brine. The organic solution was dried by filtering over a bed of Hydromatrix brand diatomaceous earth and concentrating to dryness. This residue was dissolved in a small amount of DCM, applied to a dry silica gel column, and eluting with mixtures of EtOAc/hexane (1-5%).
  • EtOAc ethyl acetate
  • compound 18 (1 mmol) was dissolved in 5 mL dry THF under argon and cooled to ⁇ 78° C.
  • a 0.5 M solution of KHMDS (potassium hexamethyl-disilazane) in toluene (1.05 mL) was added to the reaction mixture and stirred at ⁇ 78° C. for 45 minutes, and then the alkyl halide R 1 —X (1.05 mmol), such as benzyl bromide, in 3 mL dry THF was added.
  • the reaction mixture was stirred at ⁇ 78° C. for 30 minutes and then allowed to warm to room temperature and stirred for 8-18 hr.
  • the desired product (compound 19) was isolated by diluting the reaction mixture with 20 mL EtOAc and washing this organic solution with water and then brine. The organic solution was dried by filtering over a bed of Hydromatrix brand diatomaceous earth and concentrating to dryness. This residue was dissolved in a small amount of DCM, applied to a dry silica gel column, and eluting with mixtures of EtOAc/hexane (1-5%).
  • compound 16 (1 mmol) was dissolved in 5 mL dry DCM under argon.
  • Crotyl bromide (1.5 mmol) and BTPP (tert-butylimino-tri(pyrrolidino)-phosphorane, 1.5 mmol) were added to the reaction mixture and stirred at room temperature for 4-18 hr.
  • the desired product (compound 22) was purified by concentrating the reaction mixture to a puddle, redissolving in a small amount of DCM, applying it to a dry silica gel column, and eluting with mixtures of EtOAc/hexane (0.5-2%).
  • the reaction was quenched by adding 1 mL of MeOH/H 2 O (1:1), concentrating the reaction mixture in vacuo, diluting the reaction mixture with 20 mL EtOAc, and washing this organic solution with water and then brine.
  • the organic solution was dried by filtering over a bed of Hydromatrix brand diatomaceous earth and concentrating it to dryness. This residue was dissolved in a small amount of DCM, applied to a dry silica gel column, and eluted with mixtures of EtOAc/hexane (5-10%) to give pure compound 19.
  • compound 19 was dissolved in 6 N HCl/THF 2:1 and stirred overnight at 70° C. This reaction mixture was cooled and extracted 3 ⁇ with EtOAc. The aqueous layer was concentrated to a puddle and redissolved in 5 mL 1 N HCl and filtered over a plug of Dowex 50WX8 ion exchange resin in the acidic form. This plug was washed with H 2 O and then the desired product was eluted with 2 N NH 4 OH. The basic solution was concentrated in vacuo to dryness, and the residue was dissolved in 10 mL 1 N HCl and lyophilized to produce purified compound 1.
  • FIG. 12 An alternative method for removing the imine protecting group is exemplified in FIG. 12 .
  • compound 33 was dissolved in 1 N HCl and stirred at room temperature for 2 hr.
  • 10 equivalents of phenyl boronic acid and diethyl ether was added to this reaction mixture.
  • the reaction mixture was rapidly stirred at room temperature for 12-18 hr.
  • the layers were separated and the aqueous solution was washed 2 ⁇ with diethyl ether.
  • the aqueous solution was concentrated in vacuo to dryness and the residue dissolved in 1 N HCl and lyophilized to produce purified amine 37.
  • imidazole (6.0 mmol) and triphenylphosphine (3.3 mmol) were dissolved in 15 mL DCM and cooled to 0° C. under argon. Iodine (3.3 mmol) was added to this mixture and stirred for 10-15 minutes.
  • Alkyl alcohol 24 was added in 10 mL DCM and the reaction mixture was allowed to warm to room temperature and then stirred for 12-18 hr. A few mL of saturated sodium thiosulfate solution was added along with 10-15 mL water and the mixture was stirred for 10-15 minutes. The mixture was separated and the organic layer washed 3 ⁇ with water and 1 ⁇ with brine.
  • amino alcohol 26 was Boc-protected by treating it with 1.1 equivalents of di-tent-butyl dicarbonate in DCM at room temperature for 2-4 hr. The mixture was washed 2 ⁇ with 1 N HCl and 1 ⁇ with brine. The organic solution was dried over magnesium sulfate and concentrated in vacuo to give compound 27, which was used without further purification.
  • compound 27 was treated with 2.5 equivalents imidazole and 1.1 equivalents of tert-butyl(chloro)dimethylsilane in DMF (N,N-dimethyl-formamide) at room temperature for 12-18 hr.
  • the reaction mixture was diluted with EtOAc and this organic mixture was washed 3 ⁇ with water and 1 ⁇ with brine.
  • the organic solution was dried over magnesium sulfate and concentrated in vacuo to give di-protected compound 28, which was used without further purification.
  • compound 28 was treated with 2 equivalents of di-tent-butyl dicarbonate and 0.2 equivalents of dimethylaminopyridine in acetonitrile while stirring at room temperature for 36-48 hr.
  • the reaction mixture was concentrated to dryness and the residue dissolved in EtOAc. This solution was washed 3 ⁇ with 0.1 N HCl and 1 ⁇ with brine, dried over magnesium sulfate, filtered, and concentrated in vacuo to give compound 29 which was used without further purification.
  • compound 29 was treated with 1.5 equivalents TBAF (tetrabutyl-ammonium fluoride) in THF under argon at room temperature for 3-5 hr. This mixture was diluted with EtOAc and washed 3 ⁇ with water and 1 ⁇ with brine. The organic solution was dried over magnesium sulfate and concentrated in vacuo to give di-Boc compound 30, which was used without further purification.
  • TBAF tetrabutyl-ammonium fluoride
  • This residue was dissolved in a small amount of DCM, applied to a dry silica gel column, and eluted with mixtures of EtOAc/hexane (5-10%) to give purified compound 31.
  • This compound is useful as an alkylating reagent in accordance with the synthesis methods described herein.
  • compound 32 is converted to compound 33 by treatment with 25-50% TFA (trifluoroacetic acid)/DCM under argon for 12-16 hr.
  • TFA trifluoroacetic acid
  • DCM dimethyl methacrylate
  • the reaction mixture is concentrated to dryness in vacuo, a few mL of DCM added and this solution is reconcentrated to dryness and then the residue dried in vacuo for several hr and then placed under an argon atmosphere.
  • this residue was added to 2-3 equivalents of a resin-bound amine base such as PS-DIEA (diisopropylethylamine) in DCM.
  • a resin-bound amine base such as PS-DIEA (diisopropylethylamine) in DCM.
  • an acylating agent such as acetic anhydride or benzoyl chloride
  • the reaction mixture was filtered and the resin washed with a few mL of DCM then a few mL of 1 N HCl/THF (1:2).
  • the filtrates were combined and additional 1 N HCl added. This mixture was stirred vigorously at room temperature for 12-16 hr and the organic layer separated from the aqueous layer.
  • benzophenone imine (6.68 mL, 40.0 mmol) and tert-butyl bromoacetate 15c (5.9 mL, 40.0 mmol) were dissolved in 40 mL acetonitrile.
  • DIEA (6.95 mL, 40.0 mmol) was added and the reaction mixture heated to reflux for 14 hr. The reaction mixture was cooled to room temperature, neutralized by the addition of 50% aqueous acetic acid, and cooled to 0° C. The resulting solids were collected by filtration and then washed with cold ethanol. Product 16c was dried in vacuo to give 9.05 g (77%) which was used without further purification.
  • 2-(4-bromobutyl)benzo[d][1,3,2]dioxaborole 17 was dissolved in 20 mL dry THF, pinacol (2.39 g, 20.1 mmol) was added, and the reaction mixture was stirred at room temperature for 2 hr under argon.
  • the reaction mixture was concentrated in vacuo, 50 mL of hexane was added to the residue, and it was cooled at 0° C. for 2 hr.
  • the solids were filtered and the washed with 25 mL hexane, the filtrate further diluted with 300 mL hexane, and cooled at 0° C. overnight.
  • the resin was filtered, washed 3 ⁇ with DCM, 3 ⁇ with alternating MeOH (methanol) and DCM, 3 ⁇ with MeOH, then 4 ⁇ with DCM. This resin was then treated with 75 mL 20% piperidine/DMF for 30 minutes followed by filtration and washing the resin as described above.
  • the resin-bound amine was converted to the ketimine 3 by treating with benzophenone imine (8.6 mL, 51.2 mmol) and glacial acetic acid (2.2 mL, 38.4 mmol) in 60 mL NMP overnight followed by filtration and washing the resin as described above.
  • resin 3 was treated with a mixture of compound 4a (11.2 g, 42.6 mmol, 10 eq), TBAI (tetrabutylammonium iodide, 15.7 g, 42.5 mmol, 10 eq) and BTPP (13.0 mL, 42.5 mmol, 10 eq) in 45 mL of NMP overnight followed by filtration and washing the resin as described above to give resin 5, which was dried in vacuo to give 5.39 g. Subsequently, 305 mg of resin 5 (0.60 mmol/g, 0.18 mmol) was washed with 4 ⁇ 5 mL of dry THF under an argon atmosphere.
  • TBAI tetrabutylammonium iodide, 15.7 g, 42.5 mmol, 10 eq
  • BTPP 13.0 mL, 42.5 mmol, 10 eq
  • resin 6 was washed 3 ⁇ THF/H 2 O 2:1, and then it was treated with 1 N HCl/THF 1:2 for 4 hr at room temperature followed by washing 3 ⁇ THF/H 2 O 2:1, 3 ⁇ THF, and 4 ⁇ DCM.
  • This resin was immediately treated with 95% TFA/H 2 O for 2 hr and the filtrate was collected, and the resin washed with TFA and DCM. The washes were combined with the reaction filtrate and concentrated in vacuo. This residue was immediately dissolved in 6 N HCl/THF 2:1 and stirred overnight at 70° C. This reaction mixture was cooled and extracted 3 ⁇ with EtOAc.
  • resin 6 was washed 3 ⁇ THF/H 2 O 2:1, and then treated with 1 N HCl/THF 1:2 for 4 hr at room temperature followed by washing 3 ⁇ THF/H 2 O 2:1, 3 ⁇ THF, and 4 ⁇ DCM.
  • This resin was immediately treated with 95% TFA/H 2 O for 2 hr and the filtrate was collected, the resin washed with TFA and DCM. The washes were combined with the reaction filtrate and concentrated in vacuo. This residue was immediately dissolved in 6 N HCl/THF 2:1 and stirred overnight at 70° C. This reaction mixture was cooled and extracted 3 ⁇ with EtOAc.
  • resin 6 was washed 3 ⁇ THF/H 2 O 2:1, and then treated with 1 N HCl/THF 1:2 for 4 hr at room temperature followed by washing 3 ⁇ THF/H 2 O 2:1, 3 ⁇ THF, and 4 ⁇ DCM.
  • This resin was immediately treated with 95% TFA/H 2 O for 2 hr and the filtrate was collected, the resin washed with TFA and DCM. The washes were combined with the reaction filtrate and concentrated in vacuo. This residue was immediately dissolved in 6 N HCl/THF 2:1 and stirred overnight at 70° C. This reaction mixture was cooled and extracted 3 ⁇ with EtOAc.
  • 3,4-dichlorobenzaldehyde (0.87 g, 5.0 mmol) was dissolved in 6 mL of trimethylorthoformate/NMP (2:1), added to resin 8, and mixed overnight.
  • the resin was filtered and washed 3 ⁇ DCM, 3 ⁇ alternating MeOH and DCM, 3 ⁇ with DCM to give resin 9.
  • This was further treated with compound 4a (1.02 g, 3.3 mmol) and BTPP (1.01 mL, 3.3 mmol) in 5 mL NMP for 24 hr.
  • This resin was filtered, washed 3 ⁇ with DCM, 3 ⁇ with alternating MeOH and DCM, 3 ⁇ with MeOH, then 4 ⁇ with DCM to give resin 10.
  • resin 10 was washed 3 ⁇ THF/H 2 O 2:1, and then treated with 1 N HCl/THF 1:2 for 4 hr at room temperature followed by washing 3 ⁇ THF/H 2 O 2:1, 3 ⁇ THF, and 4 ⁇ DCM.
  • This resin was immediately treated with 95% TFA/H 2 O for 2 hr and the filtrate was collected, the resin washed with TFA and DCM. The washes were combined with the reaction filtrate and concentrated in vacuo. This residue was immediately dissolved in 6 N HCl/THF 2:1 and stirred overnight at 70° C. This reaction mixture was cooled and extracted 3 ⁇ with EtOAc.
  • each compound has the following chemical structure (each example in the Table has a different R 1 group):
  • Compound 1y was obtained by treating 150 mg of compound 19i, illustrated below, with HOAc/H 2 O/THF (1:1:1) for 1 hr. Next, 90 mg of the intermediate was subjected to catalytic transfer hydrogenation (to reduce the nitro group to an amino group) in methanol with 25 mg 10% Pd/C and 0.6 g ammonium formate at room temperature for 15 minutes.
  • resin 13 was washed 3 ⁇ THF/H 2 O 2:1, and then treated with 1 N HCl/THF 1:2 for 4 hr at room temperature followed by washing 3 ⁇ THF/H 2 O 2:1, 3 ⁇ THF, and 4 ⁇ DCM.
  • This resin was immediately treated with 95% TFA/H 2 O for 2 hr and the filtrate was collected, the resin washed with TFA and DCM. The washes were combined with the reaction filtrate and concentrated in vacuo. This residue was immediately dissolved in 6 N HCl/THF 2:1 and stirred overnight at 70° C. This reaction mixture was cooled and extracted 3 ⁇ with EtOAc.
  • each compound has the following chemical structure (each example in the Table has a different R 1 group):
  • This reaction product was treated with (diethylamino)sulfur trifluoride (0.79 mL, 6.0 mmol) in 20 mL dry DCM under argon at ⁇ 78° C. for 2-8 hr.
  • the cold solution was diluted with additional dry DCM and poured into sat NaHCO 3 solution and stirred at room temperature for 30 minutes.
  • the layers were separated and the aqueous layer washed 3 ⁇ with DCM, the organic layer was washed 1 ⁇ with brine and dried over dried over MgSO 4 , filtered and concentrated to dryness in vacuo.
  • both the R and S enantiomers of compound 47 were obtained by alkylation of compound 46 as follows.
  • Compound 46 (0.82 g, 2.8 mmol) was dissolved in 10 mL dry DCM under argon. 0.42 mL (3.5 mmol) crotyl bromide, and 1.07 mL (3.5 mmol) BTPP were added. The mixture was stirred 12-16 hr at room temperature and then concentrated to dryness in vacuo. The product was purified by silica gel chromatography by eluting with 1-3% ethyl acetate/hexane to yield 0.93 g (96%) of racemic compound 47 as a clear oil.
  • Product 22 was purified by concentrating the reaction mixture to a puddle, redissolving it in a small amount of DCM, applying it to a dry silica gel column, and eluting it with mixtures of EtOAc/hexane (0.5-2%).
  • each compound has the following chemical structure (each example in the Table has a different R 1 group):
  • Compound 1aw was synthesized in accordance with the principles illustrated in FIG. 7 .
  • Compound 1ay was synthesized in accordance with the principles illustrated in FIGS. 8 and 11 , as described in detail below.
  • each compound has the following chemical structure (each example in the Table has a different R 1 group):
  • each compound has the following chemical structure (each example in the Table has a different R 1 group):
  • Compound Ma was prepared in accordance with the synthesis illustrated in FIG. 16 , wherein R 1 is a methyl group.
  • Quantitative determination of arginase activity was performed by a colorimetric method using the QuantiChromTM Arginase Assay Kit available from BioAssay Systems (Hayward, Calif., Catalog No. DARG-200), which was used according to the manufacture's protocol. Briefly, the method utilizes a chromogen that forms a colored complex specifically with urea produced in the arginase reaction. See, Mellerup, “Colorimetric method for rapid determination of serum arginase,” Clin. Chem. 13, 900-08 (1967). The intensity of the color is directly proportional to the arginase activity in the sample.
  • the rate of urea production was measured in the presence of twelve different concentrations of each potential inhibitor compound.
  • the half maximal inhibitory concentration (IC 50 ) was determined by constructing a dose-response curve. As IC 50 values are dependent upon the measurement conditions, the IC 50 values are converted to the inhibitor binding affinity (K i ) using the Cheng-Prusoff equation and the measured affinity constant (K m ) of L-arginine. See, e.g., Cheng., Cheng., Cheng., Cheng., Cheng., Cheng., Cheng., Cheng., Cheng., Cheng., Cheng., Cheng., Cheng et al., “Relationship between the inhibition constant (K l ) and the concentration of inhibitor which causes 50 percent inhibition (I 50 ) of an enzymatic reaction,” Biochem. Pharmacol. 22, 3099-108 (1973).
  • the K i values reflect the potency of these molecules to inhibit the catalytic activity of arginase to produce urea from the substrate L-arginine.
  • Lower K i values signify more effective enzyme inhibition.
  • Those compounds with the lowest (most potent) to the highest K i values (least potent) are identified by “+++,” “++,” and “+,” respectively.
  • the potencies of these examples should be compared to that of the closest prior art, racemic-ABH (“Rac-ABH”) in Table 6. That is, racemic materials were compared to racemic controls.
  • Rac-ABH racemic-ABH
  • the R 1 groups can be selected to target binding interactions in the outer active site cleft and the region flanking the outer active site clefts of arginase I and II, such that the new compounds bind more tightly than their respective parent compounds.
  • the C ⁇ -R 1 groups in the compounds of formula Ia or formula Ib of the invention can be varied to alter pharmaceutically important properties, such as crystal phase or shelf stability, absorption, biodistribution, metabolism, excretion, water solubility, lipophilicity, and the like.
  • the C ⁇ -R 1 groups of the invention can also be varied to enhance influx or prevent efflux of the compound by cellular transport proteins.
  • Contemplated equivalents of the compounds described herein include compounds that otherwise correspond thereto and that have the same general properties thereof (e.g., functioning as arginase inhibitors), wherein one or more simple variations of substituents are made that do not adversely affect the therapeutic or diagnostic efficacy of the compound.
  • the compounds of the present invention may be prepared by the methods illustrated in the reaction schemes as, for example, described herein, or by modifications thereof, using readily available starting materials, reagents, and conventional synthesis procedures. In these reactions, it is also possible to make use of variants that are in themselves known, but are not mentioned herein.
  • compounds of the invention may contain a chiral center, and they may be isolated in optically active or racemic forms. Some compounds may also exhibit polymorphism. It is therefore to be understood that the present invention encompasses any racemic, optically active, polymorphic, tautomeric, zwitterionic, or stereoisomeric form, or mixture thereof, of a compound of the invention, which possesses the useful properties described herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Transplantation (AREA)
US12/693,863 2009-01-26 2010-01-26 Arginase inhibitors and methods of use Abandoned US20100189644A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/693,863 US20100189644A1 (en) 2009-01-26 2010-01-26 Arginase inhibitors and methods of use
US14/959,765 US10118936B2 (en) 2009-01-26 2015-12-04 Arginase inhibitors and methods of use
US16/145,559 US20190127395A1 (en) 2009-01-26 2018-09-28 Arginase Inhibitors and Methods of Use
US16/548,681 US20200223871A1 (en) 2009-01-26 2019-08-22 Arginase Inhibitors and Methods of Use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14727009P 2009-01-26 2009-01-26
US12/693,863 US20100189644A1 (en) 2009-01-26 2010-01-26 Arginase inhibitors and methods of use

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/959,765 Continuation US10118936B2 (en) 2009-01-26 2015-12-04 Arginase inhibitors and methods of use

Publications (1)

Publication Number Publication Date
US20100189644A1 true US20100189644A1 (en) 2010-07-29

Family

ID=42354317

Family Applications (4)

Application Number Title Priority Date Filing Date
US12/693,863 Abandoned US20100189644A1 (en) 2009-01-26 2010-01-26 Arginase inhibitors and methods of use
US14/959,765 Expired - Fee Related US10118936B2 (en) 2009-01-26 2015-12-04 Arginase inhibitors and methods of use
US16/145,559 Abandoned US20190127395A1 (en) 2009-01-26 2018-09-28 Arginase Inhibitors and Methods of Use
US16/548,681 Abandoned US20200223871A1 (en) 2009-01-26 2019-08-22 Arginase Inhibitors and Methods of Use

Family Applications After (3)

Application Number Title Priority Date Filing Date
US14/959,765 Expired - Fee Related US10118936B2 (en) 2009-01-26 2015-12-04 Arginase inhibitors and methods of use
US16/145,559 Abandoned US20190127395A1 (en) 2009-01-26 2018-09-28 Arginase Inhibitors and Methods of Use
US16/548,681 Abandoned US20200223871A1 (en) 2009-01-26 2019-08-22 Arginase Inhibitors and Methods of Use

Country Status (17)

Country Link
US (4) US20100189644A1 (fr)
EP (1) EP2389352B1 (fr)
JP (2) JP2012515799A (fr)
CA (1) CA2749853C (fr)
CY (1) CY1121815T1 (fr)
DK (1) DK2389352T3 (fr)
ES (1) ES2729474T3 (fr)
HR (1) HRP20191433T1 (fr)
HU (1) HUE046932T2 (fr)
LT (1) LT2389352T (fr)
PL (1) PL2389352T3 (fr)
PT (1) PT2389352T (fr)
RS (1) RS58965B1 (fr)
SI (1) SI2389352T1 (fr)
SM (1) SMT201900320T1 (fr)
TR (1) TR201910726T4 (fr)
WO (1) WO2010085797A2 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120083469A1 (en) * 2010-04-22 2012-04-05 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
WO2012091757A1 (fr) * 2010-12-31 2012-07-05 Corridor Pharmaceuticals, Inc. Inhibiteurs de l'arginase et leurs procédés d'utilisation
US10065974B2 (en) 2015-10-30 2018-09-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US10098902B2 (en) 2010-10-26 2018-10-16 Mars, Incorporated Arginase inhibitors as therapeutics
US10143699B2 (en) 2015-06-23 2018-12-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US10287303B2 (en) 2016-12-22 2019-05-14 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US10391077B2 (en) 2016-05-04 2019-08-27 Oncoarendi Therapeutics S.A. Arginase inhibitors and their therapeutic applications
US10494339B2 (en) 2017-05-12 2019-12-03 Calithera Biosciences, Inc. Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide
CN113395996A (zh) * 2019-02-08 2021-09-14 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
US11291674B2 (en) 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
CN117085142A (zh) * 2023-08-04 2023-11-21 中山大学附属第七医院(深圳) 一种负载小分子药物的间充质干细胞外泌体及其制备方法与应用

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056163A1 (fr) * 2011-10-14 2013-04-18 The Regents Of The University Of California Inhibiteurs de bêta-lactamase
CN104244932B (zh) 2011-10-19 2017-02-22 马尔斯公司 精氨酸酶抑制剂和其治疗应用
US10299377B2 (en) 2011-12-22 2019-05-21 Fujifilm Corporation Conductive sheet and touch panel
WO2013158262A1 (fr) 2012-04-18 2013-10-24 Mars, Incorporated Analogues à cycle contraint en tant qu'inhibiteurs d'arginase
EP2929886B1 (fr) * 2012-12-04 2021-11-24 Aribio Inc. Composition comprenant un inhibiteur de phosphodiestérase de type 5 pour l'inhibition d'apoptose de neurones
EP3134546A4 (fr) * 2014-04-24 2017-12-06 Dana-Farber Cancer Institute, Inc. Suppresseur de tumeur et biomarqueurs oncogènes prédictifs de réponse à un inhibiteur de point de contrôle anti-immunitaire
PL410665A1 (pl) * 2014-12-29 2016-07-04 Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością Inhibitory arginazy oraz ich zastosowania terapeutyczne
AU2016335991A1 (en) * 2015-10-05 2018-05-10 Calithera Biosciences, Inc. Combination therapy with glutaminase inhibitors and immuno-oncology agents
JP6581308B2 (ja) * 2016-10-17 2019-09-25 一般社団法人 金沢大整形 癌治療剤
CR20200445A (es) 2018-03-05 2021-04-27 Arcus Biosciences Inc Inhibidores de la arginasa
AU2019246728A1 (en) 2018-03-29 2020-08-27 Oncoarendi Therapeutics S.A. Dipeptide piperidine derivatives
RU2695333C1 (ru) * 2018-09-24 2019-07-23 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемически-реперфузионных повреждений почек ингибитором аргиназы II в эксперименте
RU2696580C1 (ru) * 2018-09-25 2019-08-05 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики нарушений функций почек ингибитором аргиназы II в эксперименте
CN113382998A (zh) 2018-11-16 2021-09-10 艾库斯生物科学有限公司 Arg1和/或arg2的抑制剂
TW202228720A (zh) 2020-12-22 2022-08-01 波蘭商昂科艾倫迪治療法股份公司 精胺酸酶抑制劑及其使用方法
CN117417292B (zh) * 2023-02-20 2024-07-12 浙江新码生物医药有限公司 一种含有杂芳基的非天然氨基酸及其用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483853A (en) * 1981-08-14 1984-11-20 Collins James F Amino acid isomers, their production and their medicinal use
US6723710B2 (en) * 1997-10-10 2004-04-20 The Trustees Of The University Of Pennsylvania Compositions for inhibiting arginase activity
WO2005025620A2 (fr) * 2003-08-13 2005-03-24 Pharmacia Corporation Therapie de combinaison avec des inhibiteurs de la synthase du monoxyde d'azote inductible et des agents d'alkylation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1351674A4 (fr) * 2000-04-12 2004-12-22 Cornell Res Foundation Inc Pharmacotherapie pour dysfonction vasculaire associee a la bioactivite deficiente de l'oxyde nitrique
EP2083812B1 (fr) * 2006-11-21 2017-04-05 Rijksuniversiteit Groningen Utilisation d'inhibiteurs de l'arginase dans le traitement de l'asthme et de la rhinite allergique

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4483853A (en) * 1981-08-14 1984-11-20 Collins James F Amino acid isomers, their production and their medicinal use
US6723710B2 (en) * 1997-10-10 2004-04-20 The Trustees Of The University Of Pennsylvania Compositions for inhibiting arginase activity
WO2005025620A2 (fr) * 2003-08-13 2005-03-24 Pharmacia Corporation Therapie de combinaison avec des inhibiteurs de la synthase du monoxyde d'azote inductible et des agents d'alkylation

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Feng et al. in Angewandte Chemie International Edition 46, 3033 - 3036 (2007) *
Goldstein et al. in The New England Journal of Medicine 338(20) 1397 - 1404 (1998) *
Khosla et al. in Proc. Natl. Acad. Sci. USA 78 (1981) 757 - 76 *

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9994594B2 (en) 2010-04-22 2018-06-12 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
US10538537B2 (en) 2010-04-22 2020-01-21 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
US20120083469A1 (en) * 2010-04-22 2012-04-05 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
US9040703B2 (en) * 2010-04-22 2015-05-26 Mars, Incorporated Inhibitors of arginase and their therapeutic applications
US10098902B2 (en) 2010-10-26 2018-10-16 Mars, Incorporated Arginase inhibitors as therapeutics
US10603330B2 (en) 2010-10-26 2020-03-31 Mars, Incorporated Arginase inhibitors as therapeutics
US11389464B2 (en) 2010-10-26 2022-07-19 Mars, Incorporated Arginase inhibitors as therapeutics
US8894970B2 (en) 2010-12-31 2014-11-25 Corridor Pharmaceuticals, Inc. Arginase inhibitors and methods of use thereof
CN110123820B (zh) * 2010-12-31 2022-05-31 阿斯利康公司 精氨酸酶抑制剂及其使用方法
CN110123820A (zh) * 2010-12-31 2019-08-16 阿斯利康公司 精氨酸酶抑制剂及其使用方法
US9447122B2 (en) * 2010-12-31 2016-09-20 Astrazeneca Ab Arginase inhibitors and methods of use thereof
WO2012091757A1 (fr) * 2010-12-31 2012-07-05 Corridor Pharmaceuticals, Inc. Inhibiteurs de l'arginase et leurs procédés d'utilisation
US10143699B2 (en) 2015-06-23 2018-12-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US10905701B2 (en) 2015-06-23 2021-02-02 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US10398714B2 (en) 2015-06-23 2019-09-03 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US10851118B2 (en) 2015-10-30 2020-12-01 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US10844080B2 (en) 2015-10-30 2020-11-24 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US10065974B2 (en) 2015-10-30 2018-09-04 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US12053451B2 (en) 2016-05-04 2024-08-06 Oncoarendi Therapeutics S.A. Arginase inhibitors and their therapeutic applications
US10391077B2 (en) 2016-05-04 2019-08-27 Oncoarendi Therapeutics S.A. Arginase inhibitors and their therapeutic applications
US11291674B2 (en) 2016-11-08 2022-04-05 Calithera Biosciences, Inc. Arginase inhibitor combination therapies
US11021495B2 (en) 2016-12-22 2021-06-01 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US10287303B2 (en) 2016-12-22 2019-05-14 Calithera Biosciences, Inc. Compositions and methods for inhibiting arginase activity
US12054501B2 (en) 2016-12-22 2024-08-06 Precision Pharmaceuticals, Inc. Compositions and methods for inhibiting arginase activity
US11370754B2 (en) 2017-05-12 2022-06-28 Calithera Biosciences, Inc. Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide
US10906872B2 (en) 2017-05-12 2021-02-02 Calithera Biosciences, Inc. Method of preparing (3R,4S)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide
US10494339B2 (en) 2017-05-12 2019-12-03 Calithera Biosciences, Inc. Method of preparing (3R,4S)-3-acetamido-4-allyl-N-(tert-butyl)pyrrolidine-3-carboxamide
CN113395996A (zh) * 2019-02-08 2021-09-14 阿斯利康(瑞典)有限公司 精氨酸酶抑制剂及其使用方法
US12435097B2 (en) 2019-02-08 2025-10-07 Astrazeneca Ab Arginase inhibitors and methods of use thereof
CN117085142A (zh) * 2023-08-04 2023-11-21 中山大学附属第七医院(深圳) 一种负载小分子药物的间充质干细胞外泌体及其制备方法与应用

Also Published As

Publication number Publication date
JP6177832B2 (ja) 2017-08-09
US20190127395A1 (en) 2019-05-02
RS58965B1 (sr) 2019-08-30
WO2010085797A2 (fr) 2010-07-29
WO2010085797A3 (fr) 2010-11-04
LT2389352T (lt) 2019-06-10
US20160194340A1 (en) 2016-07-07
EP2389352A4 (fr) 2013-02-20
SMT201900320T1 (it) 2019-07-11
CA2749853C (fr) 2018-08-21
CA2749853A1 (fr) 2010-07-29
US10118936B2 (en) 2018-11-06
JP2012515799A (ja) 2012-07-12
JP2015205891A (ja) 2015-11-19
PT2389352T (pt) 2019-08-23
HUE046932T2 (hu) 2020-04-28
SI2389352T1 (sl) 2019-08-30
PL2389352T3 (pl) 2019-10-31
EP2389352B1 (fr) 2019-05-08
DK2389352T3 (da) 2019-07-29
AU2010206535A1 (en) 2011-07-28
EP2389352A2 (fr) 2011-11-30
HRP20191433T1 (hr) 2019-11-15
ES2729474T3 (es) 2019-11-04
TR201910726T4 (tr) 2019-08-21
US20200223871A1 (en) 2020-07-16
CY1121815T1 (el) 2020-07-31

Similar Documents

Publication Publication Date Title
US20200223871A1 (en) Arginase Inhibitors and Methods of Use
US9447122B2 (en) Arginase inhibitors and methods of use thereof
US11746116B2 (en) Antibiotic resistance breakers
US20190192697A1 (en) Chemical probes of lysyl oxidask-like 2 and uses thereof
US20240190790A1 (en) Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
JP6929881B2 (ja) 新規なβ−ラクタマーゼ阻害剤
AU2010206535B2 (en) Arginase inhibitors and methods of use
HK1164831A (en) Arginase inhibitors and methods of use
HK1164831B (en) Arginase inhibitors and methods of use
HK40012747A (en) Arginase inhibitors and methods of use thereof
HK40012747B (en) Arginase inhibitors and methods of use thereof
HK1213769B (zh) 精氨酸酶抑制剂及其使用方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: CORRIDOR PHARMACEUTICALS, INC., MARYLAND

Free format text: MERGER;ASSIGNORS:IMMUNE CONTROL INC.;ARGINETIX, INC.;REEL/FRAME:027121/0692

Effective date: 20100611

AS Assignment

Owner name: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, PE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA;REEL/FRAME:033903/0012

Effective date: 20141007

Owner name: CORRIDOR PHARMACEUTICALS, INC., MARYLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA;REEL/FRAME:033903/0012

Effective date: 20141007

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:UNIVERSITY OF PENNSYLVANIA;REEL/FRAME:034014/0463

Effective date: 20141001

AS Assignment

Owner name: ASTRAZENECA UK LIMITED, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CORRIDOR PHARMACEUTICALS, INC.;REEL/FRAME:035190/0139

Effective date: 20141022

Owner name: ASTRAZENECA AB, SWEDEN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ASTRAZENECA UK LIMITED;REEL/FRAME:035222/0710

Effective date: 20150303

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, MA

Free format text: CONFIRMATORY LICENSE;ASSIGNOR:THE UNIVERSITY OF PENNSYLVANIA;REEL/FRAME:047519/0967

Effective date: 20181115